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AB-type protein toxins have a catalytic A subunit attached to a cell-binding B subunit. Ricin, Shiga 
toxin (Stx), exotoxin A, and diphtheria toxin are AB toxins that act within the host cytosol and kill 
the host cell through pathways involving the inhibition of protein synthesis. Our overall goal is to 
help elucidate the cellular basis of intoxication for therapeutic development. According to the 
current model of intoxication, the effect of AB toxins is irreversible. To test this model, we 
developed a system that uses flow cytometry and a fluorescent reporter to examine the cellular 
potency of toxins that inhibit protein synthesis. Our data show that cells can recover from 
intoxication: cells with a partial loss of protein synthesis will, upon removal of the toxin, increase 
the level of protein production and survive the toxin exposure. This work challenges the prevailing 
model of intoxication by suggesting ongoing toxin delivery to the cytosol is required to maintain 
the inhibition of protein synthesis and ultimately cause apoptosis. We also used our system to 
examine the basis for the greater cellular potency of Stx1 in comparison to Stx2. We found that 
cells intoxicated with Stx1a behave differently than those intoxicated with Stx2: cells exposed to 
Stx1a exhibited a population-wide loss of protein synthesis, while cells exposed to Stx2a or Stx2c 
exhibited a dose-dependent bimodal response in which one subpopulation of cells was unaffected 
(i.e., no loss of protein synthesis). Additional experiments indicated the identity of the Stx B 
subunit is a major factor in determining the uniform vs. bimodal response to Stx subtypes. This 
work provides evidence explaining, in part, the differential toxicity between Stx1 and Stx2. 
Overall, our collective observations provide experimental support for the development of 
inhibitors and post-exposure therapeutics that restrict, but not necessarily block, toxin delivery to 




Shiga toxin (Stx), ricin, exotoxin A (EtxA), and diphtheria toxin (Dtx) are AB-type protein toxins 
that act within the host cytosol and kill the host cell through pathways involving the inhibition of 
protein synthesis. According to the standard model, intoxication is seen as an irreversible process 
because it is believed that a single molecule of cytosolic toxin is sufficient to kill the host cell. 
Despite the fact that there is lack of convincing evidence to support the “one molecule” model, 
intoxication has nonetheless been widely viewed as an irreversible process. Thus, our overall goal 
is to help elucidate the cellular basis of intoxication for therapeutic development. Using flow 
cytometry and a fluorescent reporter system to monitor protein synthesis, this study found that a 
single molecule of cytosolic toxin is not sufficient for complete inhibition of protein synthesis or 
cell death. Furthermore, contradictory to the standard model, our results show that cells can recover 
from intoxication: cells with a partial loss of protein synthesis will, upon removal of the toxin, 
increase the level of protein production and survive the toxin challenge. Thus, ongoing toxin 
delivery to the cytosol appears to be required for the death of cells exposed to sub-optimal toxin 
concentrations. 
 
We also used our cytofluorometry assay to study the potency of Stxs. Enterohemorrhagic Shiga 
toxin-producing Escherichia coli (STEC) strains like E. coli O157:H7 are a major public health 
concern worldwide. STEC strains produce Stx as their main virulence factor. There are two major 
antigenic forms of Stx, Stx1 and Stx2. Both forms have minor variants, which differ in potency. It 
has been shown that Stx2a is more potent in animal studies, while Stx1a is more toxic to Vero 
cells. The factors contributing to the differential potency of Stx subtypes are poorly understood. 
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Our results suggest that the differential potencies between Stx subtypes are partly due to the 
amount of toxin that reaches the cytosol of the host cell. When a cell population was intoxicated 
with Stx1a, a uniform loss in protein synthesis was observed. A cell population intoxicated with 
Stx2a and Stx2c, on the other hand, exhibited a bimodal cell distribution in which some of cells 
were intoxicated and some were not. Additional cytofluorometry experiments conducted to 
understand the bimodal response in cells exposed to Stx2 subtypes found that cells bind more 
Stx1a than Stx2a. Furthermore, experiments conducted with hybrid toxins in which the subunits 
of the Stx subtypes were swapped suggest that the identity of the B subunit is partly responsible 
for the different cellular responses. Cells that were challenged with a hybrid toxin in which the A1 
subunit of Stx1a was combined with the B subunit of Stx2a exhibited a bimodal response to 
intoxication similar to the response observed with Stx2a holotoxin, while cells challenged with a 
hybrid toxin in which the A1 subunit of Stx2a was combined with the B subunit of Stx1a exhibited 
a population-wide loss of protein synthesis similar to that observed with Stx1a holotoxin. 
 
In summary, this work presents evidence that challenges the “one molecule” model and the long-
standing paradigm suggesting that intoxication is an irreversible process. Moreover, this work 
provides supporting evidence explaining, in part, the differential potency between Stx1 and Stx2 
subtypes. These collective observations suggest there is a need to accumulate a substantial pool of 
cytosolic toxin to maintain the inhibition of protein synthesis and induce cell death. Thus, these 
observations provide experimental support for the development of inhibitors and post-exposure 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
AB toxins are virulence factors produced by a variety of bacterial pathogens and some plants (1). 
They are protein toxins that are released into the extracellular environment but attack targets within 
the host cytoplasm (2, 3). These toxins initially enter the cell through receptor-mediated 
endocytosis and reach the cytosol between 30 minutes and 2 hours after internalization from the 
plasma membrane (4-7). AB toxins share the same basic structural characteristic: a catalytically 
active A subunit and a cell-binding B subunit (Fig. 1). This study will examine four AB toxins: 
Shiga toxin (Stx), ricin, exotoxin A (EtxA), and diphtheria toxin (Dtx). These toxins affect the host 
cells by inhibiting protein synthesis. The A and B moieties for each toxin can encompass different 
regions of a single polypeptide chain or may represent distinct proteins in various stoichiometries 
(e.g., AB, AB2, AB5, A3B7). Ricin, EtxA, and Dtx are single proteins comprised of one A subunit 
and one B subunit that represent an AB stoichiometry. The A subunit of EtxA and Dtx contains a 
single region, while their B subunits are comprised of two distinct regions. Stx, on the other hand, 
represents an AB5 stoichiometry made of two proteins, StxA and StxB. The StxA subunit is 
comprised of two distinct domains: a catalytically active StxA1 and a StxA2 linker. The StxB 
subunit is made of five identical B domains assembled as a homopentamer. Two of the AB toxins 
examined throughout this study, Stx and ricin, inhibit protein synthesis via inactivation of the 28S 
ribosomal RNA (rRNA), while the other two, EtxA and Dtx, inhibit protein synthesis through 
inactivation of elongation factor 2 (eEF2) (8-12).  
 
AB-type protein toxins all have a cellular receptor on the host plasma membrane and a cytosolic 
target. After binding to a specific receptor, these toxins are internalized and delivered to the 
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endosomes. Some enter the cytosol directly from the endosomes, while others move from the 
endosomes to the endoplasmic reticulum (ER) before entering the cytosol (1, 13). Only a small 
amount of internalized toxin reaches the cytosol of the host cell (14-17). A large proportion of 
internalized toxin is recycled to the surface of the host cell and/or degraded by the lysosomes. 
Unfortunately for the host cell, the small percentage of toxin that makes it to the cytosol is very 
effective. Our overall goal is to understand the cellular mechanism of intoxication by AB toxins. 
A better understanding on how these toxins work at the cellular level is essential for the 
development of effective therapeutics against their associated diseases.  
 
As summarized in Table 1, the combination of receptor, entry mechanism, translocation site, 
cytosolic target, and action on the target are different for each AB toxin. Depending on the type of 
receptor used by an AB toxin, internalization takes place by exploiting the host cell endocytic 
pathway in a clathrin-dependent and/or clathrin-independent fashion. Some AB toxins move into 
the cytosol from acidified endosomes, while others follow an inefficient transport pathway to the 
ER before entering the cytosol. Dtx inhibits protein synthesis and belongs to the subset of toxins 
that cross the endosomal membrane to reach the cytosol (18); ER-translocating toxins that inhibit 
protein synthesis include Stx, ricin, and EtxA (13, 19, 20) (Fig. 2). A brief overview on the 
mechanism of action of each of the toxin will be provided next in order to establish what is 





Figure 1. Structural organization of Stx1a, Stx2a, ricin, EtxA, Dtx. 
(A) Ribbon diagram of Stx1a (PDB 1DM0, (21)) and (B) Stx2a (PDB 1R4P, (22). The A1 subunit is depicted in red; 
the A2 linker is depicted in yellow; and the B homopentamer is depicted in blue. StxB binds to Gb3/Gb4 on the surface 
of the host cell, while StxA1 is an N-glycosydase that inhibits protein synthesis by removing a specific adenine residue 
from the 28S rRNA. (C) Ribbon diagram of ricin (PDB 2AAI, (23)). The catalytic A subunit is depicted in red and 
the cell-binding B subunit is depicted in blue. The B subunit of ricin binds to glycoproteins and glycolipids with 
terminal galactose residues, while the A subunit of ricin inhibits protein synthesis through its N-glycosidase activity 
that specifically removes an adenine residue from the 28S rRNA. (D) Ribbon diagram of EtxA (PDB 1IKQ, (24)). 
The catalytically active A subunit is depicted in red, while the B subunit containing the translocation domain and the 
receptor-binding domain are depicted in light blue and blue respectively. EtxA binds to α-macroglobulin receptor/low 
density lipoprotein receptor-related protein on the host plasma membrane, while the catalytic domain has ADP-
ribosyltransferase activity and inhibits protein synthesis by modifying eEF2. (E) Ribbon diagram of Dtx (PDB 
1DDT,(25)). The B fragment is located within the C-terminal domain and it is comprised of two domains, a 
translocation domain (light blue) and a receptor-binding domain (blue). The catalytic domain is located within the N-
terminal domain. Dtx binds to epidermal growth factor on the host plasma membrane, while the C domain has ADP-
ribosyltransferase activity and inhibits protein synthesis by modifying eEF2. The above ribbon diagrams were edited 





Figure 2. Mechanism of action of Stx, ricin, EtxA, and Dtx. 
The toxin binds to a receptor on the surface of the target cell. Following clathrin-dependent and/or clathrin-
independent endocytosis, ER-translocating toxins Stx, ricin, and EtxA are transported to the Golgi complex and ER, 
while Dtx is an endosome-translocating toxin that releases its catalytic subunit to the cytosol directly from the 
endosomes. The catalytic A subunit of Stx, ricin, and EtxA is first separated from the rest of the toxin before moving 
into the cytosol. The A subunits of ricin and Stx are N-glycosidases that remove an adenine moiety from the 28S 
rRNA, thereby halting protein synthesis. The A subunits of EtxA and Dtx, on the other hand, act as ADP-
ribosyltransferases and modify eEF2. These events inhibit protein synthesis and eventually result in apoptotic cell 





Ricin is a natural by-product contained in the castor bean of the Ricinus communis plant. Ricin is 
a toxin known for its malevolent use in bioterrorism and it is considered a biological weapon (26-
28). Symptoms from ricin poisoning depend on the exposure route. Inhalation and ingestion are 
the two main routes of exposure to ricin. Inhaled ricin leads to cough, respiratory problems, fever, 
nausea, and tightness in the chest. Ingested ricin, on the other hand, is a less toxic route that leads 
to severe dehydration resulting from bloody vomiting and diarrhea. The NIAID classifies ricin as 
a category B biothreat due to its ease of dissemination and its morbidity and mortality rates. Death 
from ricin depends on the route of exposure and the intoxicated dose. There are currently no known 
antidotes against ricin. Symptoms are routinely treated using supportive care like oral rehydration 
therapy.  
 
Ricin is a type II ribosome inactivating protein (RIP II). Type II RIPs are synthesized by certain 
plants like pokeweed (29, 30). RIPs possess N-glycosidase activity that the toxin uses to cleave 
the N-glycosidic bond of adenine (depurination) in ribosomal RNA sequences. Type I RIPs are 
composed of a single catalytic subunit, whereas type II RIPs have an AB organization composed 
of a catalytic domain and a lectin domain that binds to cell surfaces. RIPs are known to be used by 
plants as an antiviral mechanism (29-31), and they have abortifacient activities that are reported to 
be used in Chinese medicine (32).  
 
Ricin is a single-chain AB-type protein toxin made of a catalytic A subunit linked to a lectin B 
subunit via a disulfide bond. Using its B subunit, ricin binds to galactose residue located on 
glycoproteins and glycolipids on the cell surfaces (33, 34). Reduction of the disulfide bond of ricin 
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takes place in ER following transport from the early endosome (EE) to the Golgi via clathrin-
dependent and clathrin-independent endocytosis (35, 36). Following the reduction of its disulfide 
bond, the catalytic A subunit of ricin exploits the ER-associated degradation (ERAD) quality 
control process to enter the cytosol through the Sec61p translocon (16, 37, 38). In the cytoplasm, 
the A subunit of ricin acts on its target, the 28S rRNA, by removing an adenine residue from the 
“sarcin/ricin loop” (12, 39). Depurination of the 28S rRNA takes place in a hydrolytic manner by 
the cleavage of the adenine residue at position 4324 (A4324) (40). Ricin-induced removal of A4324 
interferes with the proper interaction between the ribosome and eEF2, thereby leading to inhibition 
of protein synthesis and, ultimately, apoptotic cell death (8, 9, 12).  
 
Diphtheria toxin (Dtx) 
Dtx is secreted by the Gram-positive bacterium Corynebacterium diphtheriae (41-43). Dtx is the 
main cause of the respiratory infection diphtheria that is transmitted from person to person through 
coughing and sneezing. While diphtheria is mainly a respiratory complication, absorption of Dtx 
into the bloodstream also leads to damage of nearby organs (44). Symptoms of diphtheria includes 
swollen gland in the neck, fever, and sore throat. Serious complications that result from diphtheria 
include paralysis and pneumonia. If left untreated, diphtheria infection often leads to death. 
Currently, the treatments for diphtheria are antitoxin to target Dtx and antibiotics to kill the 
bacterium. 
 
Dtx is a single protein that belongs to the AB-type protein toxin family. The B fragment of Dtx is 
contained within the C-terminal region and it is comprised of two domains, a translocation (T) 
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domain and a receptor-binding (R) domain. The catalytic (C) domain of Dtx, on the other hand, is 
located within the N-terminal region of the toxin (45). Following binding of Dtx to its cell surface 
receptor heparin-binding epidermal growth factor (HB-EGF) using its R domain, the toxin is 
internalized via clathrin-dependent endocytosis (42, 46-48). Following cleavage of Dtx between 
the C and T domains by the host protease furin, which cycles between the cell surface, endosomes, 
and the TGN, the two domains remain linked via a disulfide bond (48, 49). Once Dtx reaches the 
early endosome, the acidic environment contained within this compartment causes the T domain 
to undergo a conformational change that results in the insertion of its exposed hydrophobic regions 
into the membrane of the endosome. This forms a pore, allowing the C domain of the toxin to be 
translocated to the cytosol (18, 50). Within the cytosol of the host cell, the disulfide bond linking 
the C and T domains of Dtx gets reduced, thereby freeing the catalytic C domain of the toxin to 
modify eEF2 by transferring an ADP-ribose group from nicotinamide dinucleotide (NAD) (51-
53). Deactivation of eEF2 by ADP-ribosylation inhibits protein synthesis, thereby leading to 
apoptotic cell death (54, 55).  
Exotoxin A (EtxA) 
EtxA is a single protein secreted by the Gram-negative bacterium Pseudomonas aeruginosa. It is 
an environmental bacterium commonly linked to hospital-acquired infections such as pneumonia 
and sepsis syndrome. Immunocompromised patients are often vulnerable to Pseudomonas 
infections. Pseudomonas infections can be treated using antibiotics. However, multi-drug resistant 




EtxA belongs to the AB-type protein toxin family comprised of three main functional domains: an 
N-terminal receptor-binding (R) domain, a translocation (T) domain, and a catalytic (C) domain 
(56, 57). EtxA binds to the low-density lipoprotein receptor-related protein (LRP) and enters the 
host cell through clathrin-coated endocytic vesicles (58, 59). At an early stage during the EtxA 
cellular intoxication pathway, plasma membrane carboxypeptidases engage the REDLK peptide 
sequence at the C-terminus of the toxin to remove the lysine residue (60, 61). A furin protease in 
the endosomes and/or the TGN cleaves the C and T terminal domains of EtxA in a manner similar 
to the cleavage of Dtx (49, 62-64). Following cleavage of the C and T terminal domains, the 
catalytic C domain, still attached to the T domain, migrates to the TGN through Rab9-dependent 
transport (65, 66). The disulfide-linked C and T domains are subsequently reduced presumably by 
protein disulfide isomerase (PDI) or PDI-like enzymes (66). Once located in the Golgi, the C-
terminus of the toxin binds to a KDEL receptor using the C-terminal REDL sequence. This 
facilitates the transport of the catalytic C domain to the ER (67). Translocation of the C domain to 
the cytosol of the host cell is facilitated by the attached T domain (68, 69). The catalytic action of 
the cytosolic C domain inactivates its eEF2 target by ADP-ribosylation (70). The resulting 
inactivation of eEF2 leads to protein synthesis inhibition and, ultimately, apoptotic cell death.  
Shiga toxin (Stx) 
Stx is an AB-type protein toxin secreted by the Gram-negative bacterium Shigella dysenteriae, the 
first known species of Shigella. The toxin is named after Dr. Kiyoshi Shiga, who first isolated 
Shigella dysenteriae in 1896 (71-73). Other types of bacteria such as enterohemorrhagic 
Escherichia coli (EHEC) also secrete Stx as a virulence factor. Stxs secreted by STEC strains are 
often referred to as Shiga-like toxins (74). There are two main forms of Stx: Stx1 and Stx2. Stx1 
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is more potent in cell culture than Stx2. The factors contributing to the difference in potency are 
not fully understood. STEC strains are a major public health concern worldwide, and STEC 
serotype O157:H7 is frequently associated with human gastroenteritis outbreaks in industrialized 
countries (75). Symptoms of STEC infections include bloody diarrhea, vomiting, and fever. STEC 
infections can range from mild to life-threatening conditions such as hemolytic-uremic syndrome 
(HUS), a type of kidney failure (75, 76). The best treatment for STEC infections is supportive 
therapy, like hydration, against the symptoms. The use of antibiotics as treatment against STEC 
infections is highly discouraged as it may increase the risk of developing HUS by facilitating the 
release of Stx (77, 78).  
 
Stx has a catalytic A subunit (StxA) and a binding B subunit (StxB), which places it in the family 
of AB toxins (79). StxA is proteolytically nicked to generate a disulfide-linked heterodimer 
composed of an enzymatic A1 fragment and an A2 fragment that extends into the central pore of 
the ring-like StxB homopentamer. StxB binding to globotriaosyl ceramide (Gb3) and/or 
globotetraosyl ceramide (Gb4) on the surface of a target cell leads to endocytosis through clathrin-
coated pits (80-82). The host protease furin cleaves the holotoxin-associated StxA subunit in the 
endosomes and/or TGN to generate the StxA1/StxA2 heterodimer (83). The toxin then moves by 
retrograde transport to the ER where reduction of the StxA1/StxA2 disulfide bond allows StxA1 
to dissociate from the rest of the toxin before entering the cytosol (84). In the cytosol, StxA1 
irreversibly inactivates the ribosome through the removal of an adenine residue from the 28S 
rRNA of the 60S ribosomal subunit. Depurination of the ribosome interferes with protein 




Table 1. Toxin comparison chart. 
Receptor, entry mechanism, translocation site, cytosolic target, and action on the target are summarized for Stx, ricin, EtxA, and Dtx. 
 











































Probability and proportionality models of intoxication 
Table 1 summarizes several differences in the mechanism of action between AB toxins. The factors 
that contribute to these differences dictate the overall potency of the toxin. Many aspects of the 
molecular mechanism of intoxication and overall potency of these toxins are still poorly 
characterized. It is widely believed that the effect of AB toxins is irreversible. According to the 
standard model, as few as one molecule of cytosolic toxin is sufficient to completely inhibit protein 
synthesis and cause cell death (6, 86-88). This “one molecule” model is a probability model 
implying that, at the half maximal dose of a toxin (ED50), half of the cells within a population 
receive at least one molecule of toxin and the other half receive no toxin. An alternate model of 
intoxication is the proportionality model, which implies that all cells within a population receive 
varying amounts of toxin. Per the proportionality model of intoxication, a toxin ED50 would 
indicate that all cells receive toxin, but most receive a quantity of toxin that results in 50% 
inhibition of protein synthesis. Most current systems that monitor toxin activity average the results 
from a population of cells and therefore cannot differentiate intoxicated cells from unintoxicated 
cells. In order to have a better understanding about the cellular potency of toxin, their effect must 
be monitored in single cell systems that can distinguish between the probability and proportionality 




CHAPTER 2: SPECIFIC AIMS AND RATIONALE 
The purpose of this study is to examine two proposed models by which AB-type protein toxins 
affect the host cell. The probability model will be evaluated to determine the validity of the “one 
molecule” model for a subset of AB toxins that inhibit protein synthesis. In this model, a toxin 
ED50 implies that only half of the cells are intoxicated. The proportionality model, on the other 
hand, will be examined to determine whether all cells receive toxin. In this model, a toxin ED50 
implies that all cells are intoxicated but the extent of intoxication is directly related to how much 
toxin is in the cytosol. It is important to differentiate between the two models of intoxication to 
determine whether intoxication is an all or nothing event. The probability model suggests that cells 
cannot recover, whereas the proportionality model suggest that cells can potentially recover. 
Therefore, this determination is important for the development of post-exposure therapeutics. Most 
of the quantitative systems that are currently available to monitor the toxin-induced inhibition of 
protein synthesis average results from population of cells (89, 90). One of the main limitations that 
these systems present is that they cannot differentiate intoxicated cells from unintoxicated cells. 
Thus, these two models cannot be examined and differentiated by analyzing data obtained from 
currently available systems.  
 
To differentiate between the probability and proportionality models of intoxication, a novel system 
that can monitor toxin activity in individual cells was developed. This new system is an alternative 
approach in which intoxicated cells can be differentiated from unintoxicated cells. The specific 
aims of this study were to (i) develop a novel system to investigate the mechanism of action of AB 
toxins in individual cells; (ii) examine the potential cellular recovery from exposure to a subset of 
13 
 
AB toxins using the new system; and (iii) examine the cellular basis for the differential potency 
between Stx subtypes. The alternative approach used in this study to examine the activity of toxins 
that inhibit protein synthesis will provide new insights about the cellular potencies of these toxins 
that would otherwise not be possible to detect using current systems that average results from 
population of cells. 
Aim I: Develop a new system to examine the activity of toxins that inhibit protein synthesis 
Several methods can detect the toxin-induced inhibition of protein synthesis or resulting cell death. 
A common procedure measures the viability of intoxicated cells by dye exclusion, MTS/MTT 
assay, or similar protocols (91-96). However, most of these methods require several days of toxin 
exposure and often involve additional processing steps for data collection. A direct method to 
quantify the toxin-induced inhibition of protein synthesis measures the incorporation of 
radiolabeled amino acids into newly synthesized proteins (97, 98). This requires the handling of 
radioisotopes, which is laborious, potentially hazardous, and can only accommodate a limited 
number of samples. Quantitative luciferase-based assays have been described that are similar to 
the system reported here, but these systems require several preparatory and/or processing steps to 
enact the detection method (99, 100). A recently described assay that monitors the production and 
secretion of acetylcholinesterase likewise requires additional processing steps for data acquisition 
(101). The main limitation for these existing technologies is that they average results obtained 
from population of cells. As previously mentioned, one cannot differentiate between the 
probability and the proportionality models of intoxication by averaging results obtained from 
population of cells. Therefore, the novel cytofluorometry-based system described in the present 
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study is a new tool that can be used to elucidate additional aspects of AB toxins potency in cell 
culture. 
 
Assays that average the results from a population of cells make it difficult to distinguish between 
the “probability” and “proportionality” models of intoxication. As an alternative approach to 
monitor the activity of toxins that inhibit protein synthesis, we will use flow cytometry in 
conjunction with a Vero cell line that expresses a destabilized variant of the enhanced green 
fluorescent protein (EGFP) that is degraded by the proteasome with a 2-hour half-life, Vero-
d2EGFP cells (102). Intoxicated cells degrade d2EGFP and do not replenish the lost protein due 
to the toxin-induced block of protein synthesis. The fluorescence level of EGFP is thus inversely 
proportional to toxin activity (Fig. 3). Using this cell-based assay, a direct, proportional link 
between the specific loss of d2EGFP intensity and the overall loss of protein synthesis in a 
population of toxin-treated cells has been recorded with a plate reader (103). Subsequent studies 
further documented the usefulness of the Vero-d2EGFP cells for measuring the activity of AB 
toxins (90, 104-107). Other investigators have used similar cell-based toxicity assays with 
destabilized reporters (99, 108, 109) and have documented a direct correlation between the toxin-
induced inhibition of total protein synthesis and the toxin-induced loss of reporter signal (100). 
Here, our Vero-d2EGFP system was adopted to monitor the activity of toxins against individual 
cells within the population of toxin-treated cells. This new protocol will help further elucidate the 





Figure 3. Vero-d2EGFP cell-based assay.  
(A) The Vero-d2EGFP cells stably expresses a GFP reporter that has a 2-hour half-life. (B) The degraded EGFP is not 
replenished in the presence of toxins that inhibit protein synthesis, thereby resulting in decreased fluorescence 





Aim II: Determine the intoxication model for a subset of AB toxins and the potential for 
cellular recovery from intoxication 
The overall goal of this study is to help better understand the cellular basis of intoxication for a 
subset of AB toxins that inhibit protein synthesis. According to the standard model of intoxication, 
about one molecule of AB toxin entering the cytosol of the host cell is sufficient to inhibit protein 
synthesis and kill a cell (6, 86-88). Based on this model, intoxication has generally been viewed 
as an irreversible process. The data supporting this model are not convincing. Most of the studies 
supporting this model use systems that average results from population of cells (6, 86, 88, 110-
113). Additionally, these studies use systems that cannot differentiate cells that are intoxicated 
from cells that are not intoxicated. Furthermore, the results from these studies rely on 
extrapolations with toxin serial dilutions and/or kinetic analyses of intoxication. With the current 
assays, dose response curves generated with AB toxins are thought to reflect the probability of 
single cell intoxication in a population of cells. By this model, which represents the current 
working paradigm, the ED50 of a toxin represents an all-or-nothing event in which half the exposed 
cells contain no cytosolic toxin and are therefore unaffected, while the other half exhibits the full 
effects of intoxication. An alternative interpretation for toxin ED50 values is based on 
proportionality rather than probability: at the ED50 for protein synthesis inhibition, it is possible 
that all cells in the exposed population contain an amount of cytosolic toxin that only reduces 
protein synthesis by 50%. With this proportionality model, limiting but not eliminating the quantity 
of cytosolic toxin could protect a cell from the lethal outcome of intoxication.  
 
Based on the long-standing model that a single or a few molecules of cytosolic toxin are sufficient 
to completely inhibit protein synthesis and kill the cell, cellular recovery from exposure to as a 
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little as one molecule of toxin seems unlikely. The catalytic A chains of these toxins were 
originally believed to be quite stable in the host cytosol due to their relatively few lysine residues 
that allow them to escape ubiquitin-mediated proteolysis (2, 112, 114). Direct evidence in support 
of this assertion, however, is lacking. A single molecule of stable cytosolic toxin could, with time, 
theoretically block all protein synthesis and kill the cell. This theory, if true, would imply the 
implausibility of recovery once the host cell is exposed to as little as one molecule of toxin. 
However, there have been several studies indicating that toxin A chains are not stable in the 
cytosol: several studies have directly or indirectly documented the proteasome-dependent 
degradation of cytosolic toxin (115-119). These findings suggest that the severity of AB 
intoxication depends on the quantity of the A chain present in the cytosol of the host cell. Thus, 
this study examined the potential cellular recovery from exposure to AB toxins using a different 
approach.  
 
Using the current systems to study AB toxins, one cannot differentiate cells that receive toxin from 
cells that do not. This issue has important implications for inhibitor development, as the potentially 
lethal effect resulting from a single molecule of cytosolic toxin would greatly limit treatment 
regimens that are not 100% effective or target the cell-associated toxin after first contact. 
Therefore, a new approach using a different system is needed in order to test the validity of the 
“one molecule” model of intoxication. Our study used a cytofluorometry-based system to 
investigate the activity of a subset of AB toxins that inhibit protein synthesis in individual cells. 
Using this new system, we examined how individual cells in a population respond to AB toxins 
that inhibit protein synthesis. This work presented evidence with quantifiable data to help 
understand models of intoxication used by a subset of AB toxins that inhibit protein synthesis. 
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Aim III: Investigate factors that contribute to the cellular potency of Stx subtypes 
Stx is an AB-type protein toxin that inhibits protein synthesis by using its N-glycosidase activity 
to depurinate the 28S rRNA. There are two major antigenic forms of Stx, Stx1 and Stx2 (120). 
Moreover, Stx1 and Stx2 are composed of a diverse and heterogeneous group of subtypes (121-
124). These subtypes differ in potency and species specificity, with Stx2a and Stx2c frequently 
linked to human disease (13, 125). Stx2a is associated with more severe infections than the other 
Stx2 subtypes or Stx1 subtypes (76, 125-129). In contrast, Stx1a is more toxic to cultured Vero 
cells than Stx2 subtypes (130, 131). The factors contributing to these differences in potency are 
poorly understood. Therefore, this study also used the newly developed system to examine the 
differential toxicity between Stx subtypes in individual cells. The B subunits of Stx1a and Stx2a 
share nearly 60% sequence similarity and use the same Gb3 globoside as their primary surface 
receptor (132, 133), but several studies have nonetheless highlighted the role of the B subunit in 
the differential toxicity of Stx subtypes (131, 134, 135). In vitro, Stx1a has a greater affinity for 
Gb3 than Stx2a (130, 135-138). This has led to models suggesting the B subunit is responsible for 
the differential potency of Stx subtypes. Studies with hybrid toxins have provided further support 
for this model. The O’Brien lab has shown that a hybrid Stx comprising the A1 subunit of Stx1a 
with the A2 and B subunits of Stx2a (Stx 122) is less potent in Vero cells than a hybrid toxin 
comprised of the A1 subunit of Stx2a with the A2 and B subunits of Stx1a (Stx 211) (139). Studies 
investigating the difference in potency between Stx subtypes have also highlighted the role of the 
A1 subunit in their differential toxicity. Basu et al. showed that the A1 subunit of Stx2a has a 
higher affinity for the ribosome and higher catalytic activity than the A1 of Stx1a. Thus, the A1 
subunit is also a factor contributing to the differential potency of Stx subtypes (140). Further 
studies on the cellular actions of the A and B subunits are therefore needed in order to better 
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understand the differential toxicity between Stx subtypes. Therefore, this study used a 
cytofluorometry-based approach to further understand and elucidate some of the additional factors 
that contribute to the cellular potency of Stx subtypes.  
 
In this study, we will examine the basis for the different cellular potencies of Stx subtypes. Flow 
cytometry in conjunction with a GFP reporter system will be used to monitor the Stx-induced 
inhibition of protein synthesis in individual cells. With this strategy, we will examine the dose-
dependent cellular response to the main Stx subtypes. It has been shown that the B-pentamer of 
Stx1a is more stable than that of Stx2a (141, 142). More insights about the molecular basis for this 
difference in holotoxin stability is provided through an examination on the structures of the B-
pentamers. The B subunit of Stx2a contains a destabilizing amino acid residue, Gln40, that lies in 
a hydrophobic pocket, while Leu41 is the corresponding hydrophobic residue for Stx1a that 
potentially contribute to its more stable structure (143). Moreover, each of the 5 B subunit 
monomers has up to three binding sites. For Stx2a, one of the Gb3-binding sites is partially blocked 
by the Stx2 A2 linker (22, 144, 145). Thus, previous experimental evidence suggest that the 
cellular potency of a Stx subtype is linked to the stability, identity, and affinity of the B-pentamer. 
Therefore, this study aims to explain, in part, the molecular basis for the differential cellular 
toxicity between Stx1 and Stx2 subtypes and the resulting implications for the cell biology of Stxs. 
Hence, we will use a new experimental approach to investigate the involvement of the B subunit 
of Stx1a and Stx2a in the differential cellular potency of Stx subtypes.  
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Significance and implication 
There have been numerous studies highlighting the mechanism of action of AB-type protein 
toxins. However, a lot remains unknown about the mechanism of action of these toxins. 
Furthermore, AB toxins and chimeric AB toxins involving ricin, Dtx, and EtxA are being 
investigated as anti-cancer agents because their mode of action ultimately kill cells (88, 146). Type 
II RIPs, for example, have been shown to exhibit higher toxicity in cancer cells as compared to 
normal cells (147). It has been suggested that the high toxicity to cancer cells may be due to the 
fact that these cells have a higher rate of protein synthesis than normal cells (31). Thus, studies on 
RIPs like ricin, and other similar toxins, are being explored as immunotoxins and conjugates that 
can potentially be used in cancer therapy (148-150). As of today, the use of these toxins as cancer 
therapy has not yet been successful. Thus, a better understanding on how AB-type protein toxins 
work at the cellular level will be beneficial in the development of effective immunotoxins.  
 
In this study, we will use a new system to assess the validity of the long-standing paradigm 
regarding the cellular potency of AB toxins. Moreover, the new system will be used to examine 
and better understand the differential cellular potency between Stx subtypes. The novelty of the 
present work lies in the fact that no other studies have previously examined and determined the 
intoxication models employed by AB-type protein toxins. The data that can be gathered using this 
new system and the insights that can be gained from these data cannot be accomplished using 
existing systems that average results from population of cells. Consequently, the new findings 
from this study can potentially be used as a foundation in the development of new therapeutics 
against diseases caused by AB toxins as well as in the development of immunotoxins to target 
cancer cells.  
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CHAPTER 3: MATERIALS AND METHODS 
Cell culture materials 
 Parental Vero cells (ATCC #CCL-81; Manassas, VA) and a clonal population of Vero-
2dEGFP cells with stable, constitutive expression of the d2EGFP reporter (90, 103). 
 100× 20 mm tissue culture dishes (Techno Plastic Products; Switzerland). 
 Costar flat bottom cell culture 24 well plates (Techno Plastic Products; Switzerland). 
 Black-walled 24 well plates with glass bottom (Cellvis; Mountain View, CA) 
 Costar black-walled 96 well polystyrene plates with a clear, flat bottom (Corning Inc.; 
Kennebunk, ME). 
 Costar flat bottom cell culture 96 well plates (Techno Plastic Products; Switzerland). 
 Complete Dulbecco’s Modified Eagle Medium (DMEM) for carrying cells: DMEM, high 
glucose (4.5 g/L d-glucose) with 584 mg/L l-glutamine and 110 mg/L sodium pyruvate 
(GIBCO; Waltham, MA), supplemented with 10% fetal bovine serum (Atlanta Biologicals; 
Flowery Branch, GA), 1% antibiotic-antimycotic solution, and 1 mg/mL Geneticin (G-418) 
(GIBCO; Waltham, MA). Geneticin was used as the selective pressure for isolation of the 
Vero-d2EGFP cell line. Maintaining drug selection (1 mg/mL) in the passage medium of the 
Vero-d2EGFP cells ensures continued, uniform expression of the EGFP reporter. 
 Intoxication medium: F-12 + GlutaMAX-I nutrient mixture (Ham’s F-12) (GIBCO; Waltham, 
MA). 
 HyClone antibiotic-antimycotic 100× solution: 10,000 U/mL penicillin, 10,000 μg/mL 
streptomycin, and 25 μg/mL amphotericin B (GE Healthcare; Logan, UT). 
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 Trypsin-EDTA 1× solution containing 0.25% trypsin, 0.9 mM EDTA, and phenol red (GIBCO; 
Waltham, MA). 
 HyClone phosphate-buffered saline (PBS) 1× solution: 6.7 mM PO4 without calcium or 
magnesium (GE Healthcare; Logan, UT). 
Routine protocol for plating cells  
 Maintain the parental Vero and Vero-d2EGFP cells in a DMEM-based medium and passage 
when the cells form a >90% confluent monolayer on a 10 cm dish. 
  Working in a tissue culture hood, remove the spent medium from the tissue culture dish and 
wash the cells with 10 mL of sterile 1× PBS. 
 Detach cells from the dish by adding 1 mL of trypsin/EDTA for about 10 minutes at room 
temperature. 
 Resuspend detached cells in 9 mL of complete DMEM medium for a total volume of 10 mL. 
 Determine the cell concentration with a hemocytometer before seeding plates with appropriate 
amount of cells. 
 Grow cells for ~24 hours at 37°C in a 5% CO2 humidified incubator. 
Toxins 
 Ricin agglutinin II was purchased from Vector Laboratories (Burlingame, CA).  
 Stx1a was obtained from BEI Resources (Manassas, VA) or Dr. Alison O’Brien (Uniformed 
Services University of the Health Sciences (USUHS) (Bethesda, MD). 




 EtxA and Dtx were purchased from List Biologicals (Campbell, CA). 
Stx supernatant 
The plasmids encoding wild-type and hybrid Stxs (pLPSH3, pJES120, pMJS122, and pMJS211) 
were kindly provided by Dr. Angela Melton-Celsa, Department of Microbiology and Immunology, 
USUHS (Bethesda, MD) (Fig. 4). The toxin-containing cell extracts from transformed E. coli strain 
BL21(DE3)pLysS were generated following a previously established protocol (151). Briefly, 
plasmids encoding Stx1a, Stx2a, Stx 122 (Stx1a A1 with the A2 and B subunits from Stx2a), or 
Stx 211 (Stx2a A1 with the A2 B subunits from Stx1a) were transformed into BL21 E. coli cells 
via heat shock. Following transformation, the samples were placed on ampicillin-containing plates 
and allowed to grow overnight at 37°C. The next day, a single colony was picked from each plate 
and grown in 5 mL ampicillin-containing LB broth overnight at 37°C. The following day, the 
bacterial cultures were expanded in 50 mL ampicillin-containing LB broth and allowed to reach 
an optical density (OD) between 0.4 and 0.6 before a 3-hour induction with 1 mM IPTG (Sigma 
Aldrich; St. Louis, MO). Following induction, the cells were pelleted at 6,000 RPM at 4°C for 20 
minutes. The collected cell pellets were resuspended in lysis buffer (300 mM NaCl, 20 mM Tris-
HCl pH 7) supplemented with protease inhibitor cocktail (Fisher Scientific; Pittsburgh, PA). 
Following incubation of the cell pellets with 0.4 mg/mL lysozyme (Fisher Scientific; Pittsburgh, 
PA) at room temperature for 30 minutes, the samples were sonicated using a Digital Sonifier® 
(Branson Ultrasonics Corporation; Danbury, CT) to generate cell extracts. Stx-containing 
supernatants were obtained by spinning the cell extracts down at maximum speed using a Prism 





Figure 4. Shiga holotoxin and hybrid Stx structures.  
Native Stx1a subunits are depicted in grey and Stx2a subunits are depicted in black. The Stx 122 hybrid is comprised 
of the A1 subunit of Stx1a with the A2B5 subunits of Stx2a, while the Stx 211 hybrid is comprised of the A1 subunit 






Antibodies against Gb3/CD77 and Gb4 were purchased from GeneTex (Irvine, CA) and Matreya 
LLC (State College, PA), respectively. A goat anti-rat IgG antibody conjugated to allophycocyanin 
(APC) was purchased from Invitrogen (San Diego, CA), and a donkey anti-rabbit IgG antibody 
conjugated to phycoerythrin (PE) was purchased from Invitrogen (San Diego, CA). 
Fluorescence measurements 
Vero or Vero-d2EGFP cells were seeded in 500 μL volume to black-walled 24 well plates with 
glass bottom or flat bottom cell culture 24 well plates at a density of 100,000 cells per well. For 
96 well plates, cells were seeded in 100 μL volume at a density of 20,000 cells per well. After an 
overnight incubation at 37°C with 5% CO2, the cells were incubated in serum-free Ham’s F-12 
medium containing 20 μg/mL of cycloheximide (Sigma Aldrich; St. Louis, MO), inhibitors, or the 
stated toxin dilutions. Following incubation, the cells were washed with 1× PBS and then bathed 
in 1× PBS for EGFP measurement using a Synergy H1 Multi-Mode Microplate Reader (Biotek; 
Winooski, VT) with bottom optics position and 485 nm excitation / 528 nm emission filter set. For 
subsequent cytofluorometry analysis, the cells were detached from the 24 well plates using 1× PBS 
without calcium and magnesium. EGFP fluorescence was measured using an Accuri C6 Flow 
Cytometer (BD Biosciences; San Jose, CA) or a CytoFLEX Flow Cytometer (Beckman Coulter; 
Fullerton, CA). All experiments recorded 10,000 events (except for the experiment in Figure 5C, 
which recorded 20,000 events). For quantification of both plate reader and cytofluorometry data, 
background levels of autofluorescence from the parental Vero cells were subtracted from the 
experimental measurements. Background-subtracted data from treated samples were expressed as 
percentages of the control value obtained from untreated Vero-d2EGFP cells. 
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[35S]-methionine incorporation  
Vero-d2EGFP cells were seeded to a 24 well plate at a density of ~100,000 cells per well and 
allowed to reach ~90% confluency overnight. The next day the spent medium was carefully 
aspirated off the wells. Then, serum-free Ham’s F-12 nutrient mix medium containing one of 
several toxin dilutions was added to the cells at 500 µL per well. A set of cells treated with serum-
free and toxin-free Ham’s F-12 nutrient mix medium was used as the 100% control value in each 
experiment. After 18-24 hours, the spent medium was carefully aspirated off the plate and 500 µL 
of methionine (met)-free DMEM (GIBCO; Waltham, MA) was added to each well for a 15 minute 
37°C incubation. Then, the met-free DMEM was aspirated off the plate and replaced with 500 µL 
of fresh met-free DMEM containing [35S]-met (PerkinElmer; Akron, OH) at a final concentration 
of 5 µCi/mL for an additional 15-minute incubation. To precipitate the proteins, 500 µL of 10% 
trichloroacetic acid (TCA) (Fisher Scientific; Pittsburgh, PA) in 1× PBS was added to each well 
and incubated at 4°C for 30 minutes. After the 30 minutes, the TCA was aspirated off the plate, 
and another 500 µL 10% TCA in 1× PBS was added to the plate for an additional 10 minutes at 
4°C. After the 10 minutes, the TCA was aspirated off and 500 µL 0.2 N NaOH was added to each 
well for 15 minutes to lyse the cells. 5 mL of scintillation solution fluid (National Diagnostics; 
Atlanta, GA) was then added to scintillation vials. Cell lysates generated in the 0.2 N NaOH were 
loaded into scintillation vials, and the acid-precipitated radiolabel was quantified with an LS 6500 
multipurpose scintillation counter (Beckman Coulter; Fullerton, CA). 
Detection of apoptosis 
Cells treated with toxin in parallel with the fluorescence experiments described above were washed 
with 1× PBS and detached from the plate with 400 μL 1× PBS lacking calcium and magnesium. 
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The cell suspension was then supplemented with 1× binding buffer (0.01 M HEPES/NaOH [pH 
7.4], 0.14 M NaCl, 0.25 mM CaCl2) containing PE annexin V and 7-AAD (BD Biosciences; San 
Jose, CA). The cell suspensions were protected from light, mixed, and incubated at room 
temperature for 15 minutes. Following this incubation, binding buffer was used to bring the final 
sample volume to 500 μL. Samples were then analyzed using an Accuri C6 Flow cytometer. 
Unintoxicated cells that were unstained, stained with PE annexin V (AV) alone, or stained with 7-
aminoactinomycin (7-AAD) alone were used to establish the quadrant for healthy, viable cells 
lacking AV and 7-ADD staining. The fraction of unintoxicated Vero-d2EGFP cells in this quadrant 
was arbitrarily set as the 100% control value, and the fraction of viable cells after toxin or H2O2 
(Fisher Scientific; Pittsburgh, PA) challenge were expressed as percentages of the control value. 
MTS viability assay 
To monitor cell viability through cellular metabolism, 20,000 Vero-d2EGFP cells were seeded in 
a 96 well plate and allowed to reach ~80% confluency overnight at 37°C under 5% CO2. Cells 
were then incubated in serum-free Ham’s F-12 containing-toxins, drugs, and/or toxins with drugs. 
Following the indicated incubation period, 20 μL of MTS reagent (Promega; Madison, WI) was 
added to each well of the plate and incubated for 3 hours at 37°C. NADPH and NADH from live, 
metabolically active cells reduce the MTS reagent into a colored formazan product that can be 
detected at an absorbance of 490 nm using a Synergy H1 Multi-Mode Microplate Reader. 
Absorbance is directly proportional to the extent of cell viability. Background readings taken from 
wells without cells were subtracted from the experimental measurements. After background 
subtraction, the absorbance value obtained from untreated control cells was arbitrarily set at 100%. 
Data from treated or intoxicated samples were then expressed as percentages of the control value. 
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As a control to ensure substantial cell death could be detected, cells were incubated with 20% 
DMSO (Fisher Scientific; Pittsburgh, PA). Each experiment was run with 6 to 12 replicate samples 
per condition.  
Light microscopy 
Vero-d2EGFP cells were seeded to 24 well plates in 500 µL volume at a density of 100,000 cells 
per well. Following overnight growth at 37°C and 5% CO2, the cells were treated with toxins 
diluted in serum-free Ham’s F-12 medium. Following incubations of the indicated times, phase 
contrast pictures were taken using a Nikon Eclipse TE200 microscope equipped with 20× objective 
lens and a Nikon Digital Sight camera (Nikon Instruments Inc.; Melville, NY). The intoxicated 
cells were not washed prior to image capture. 
Confocal microscopy 
Vero cells and Vero-d2EGFP cells were seeded to 24 well plates containing microscope cover 
glass (Fisher Scientific; Pittsburgh, PA) in 500 µL volume at a density of 100,000 cells per well. 
Following overnight growth at 37°C and 5% CO2, the cells were washed once with 1× PBS before 
being fixed for 10 minutes at room temperature with 4% paraformaldehyde (Sigma Aldrich; St. 
Louis, MO) in 1× PBS. Following the fixation reaction, the cells were washed twice with 1× PBS. 
One drop of DAPI Fluoromount-G (SouthernBiotech; Birmingham, AL) was added directly to the 
cover glass before being mounted on a microscope slide (Fisher Scientific; Pittsburgh, PA). The 
slide was then allowed to air dry prior to being examined using a Leica TCS SP5 II confocal 




Individual B subunit monomers from Stx1a and Stx2a were conjugated to Alexa Fluor 594 using 
the Alexa Fluor 594 Microscale Protein Labeling kit from Invitrogen (San Diego, CA) according 
to the manufacturer’s instruction. Briefly, 5 μL of 1 M sodium bicarbonate was added to 50 μL of 
1 mg/mL StxB subunit monomers in a reaction tube. Then, the vial of Alexa Fluor 594 
succinimidyl ester (the reactive dye) was reconstituted with 10 μL of deionized water. The 
conjugate reaction was prepared by adding 2.4 μL of reactive dye solution to the reaction tube, 
mixed thoroughly by pipetting up and down several times, and incubated at room temperature for 
15 minutes. The upper chamber of a spin filter column was filled with 800 µL of suspended resin 
gel and centrifuged at 16,000 × g for a total of 15 seconds (including run-up time). Following 
preparation of the conjugate reaction mixture, 50 µL was loaded onto the center of the resin bed 
surface and centrifuged at 16,000 × g for a total of 1 minute. The resin bed had a reddish purple 
color as indicative that the unreacted dye was retained in the filter. The resulting Alexa Fluor® 594 
dye-labeled protein fluoresces under excitation and emission maxima similar to the Texas Red® 
fluorophore, 590/617 nm.  
Stx binding assay 
Vero or Vero-EGFP cells were seeded to a 10 cm dish about two days before staining and allowed 
to reach ~90% confluency. They were then lifted from the dish with trypsin/EDTA and distributed 
to microcentrifuge tubes at a quantity of ~500,000 cells per tube. Pelleted cells (2 minutes at 8,000 
× g) were washed once with 1× PBS and incubated under moderate shaking at 4°C for 30 minutes 
in Ham's F-12 medium containing 2% BSA (Fisher Scientific; Pittsburgh, PA) and various 
concentrations of the labeled B subunit from either Stx1a or Stx2a. The cells were then washed 
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with 1× PBS, resuspended in 400 µL of 1× PBS, and processed using the red laser of an Accuri 
C6 Flow Cytometer. Cells incubated in the absence of toxin were used to establish the background 
level of autofluorescence. Pilot experiments found that cells exposed to an unlabeled toxin B 
subunit exhibited a fluorescent output that was similar to that of cells incubated without a toxin B 
subunit. 
Gb3 and Gb4 detection 
Vero cells were seeded to a 10 cm dish about two days before staining and allowed to reach ~90% 
confluency. They were then lifted from the dish with trypsin/EDTA and distributed to 
microcentrifuge tubes at a quantity of ~500,000 cells per tube. Pelleted cells (2 minutes at 8,000 × 
g) were washed once with 1× PBS and incubated under moderate shaking at 4°C for 2 hours in 
Ham's F-12 medium containing 2% BSA and a 1:250 dilution of either a rat anti-Gb3 antibody or 
a rabbit anti-Gb4 antibody. The cells were then washed once with 1× PBS and incubated under 
moderate shaking at 4°C for 1 hour in Ham's F-12 medium containing 2% BSA and a 1:250 
dilution of either an APC-conjugated goat anti-rat IgG antibody or a PE-conjugated donkey anti-
rabbit IgG antibody. The cells were then washed with 1× PBS, resuspended in 400 µL of 1× PBS, 
and processed using an Accuri C6 Flow Cytometer. When indicated, both Gb3 and Gb4 antibodies 
were added to the same population of Vero cells. To establish the background level of 




CHAPTER 4: RESULTS 
Aim I: Develop a new system to examine the activity of toxins that inhibit protein synthesis 
Cherubin P, Quiñones B, Elkahoui S, Yokoyama W, Teter K. 2017. A Cell-Based Fluorescent 
Assay to Detect the Activity of AB Toxins that Inhibit Protein Synthesis. Methods Mol Biol. 
1600:25-36. 
 
The goal of Aim I was to optimize a previously developed system to detect the activity of AB 
toxins that inhibit protein synthesis in individual cells. Moreover, the system was evaluated for its 
capability to screen for toxin inhibitors. Lastly, the advantages of our system were compared to 
current systems that are used to detect the activity of AB toxins that inhibit protein synthesis. 
Effect of ricin on Vero-d2EGFP cells  
This study used a previously generated Vero cell line that stably expresses d2EGFP-N1, an EGFP 
variant that contains a C-terminal PEST sequence for rapid degradation by the ubiquitin-
proteasome system (102, 103). Steady-state fluorescence in the Vero-d2EGFP cell line is easily 
detected by flow cytometry, microscopy (Fig. 5), or with a plate reader. When challenged with a 
toxin that inhibits protein synthesis, toxin-susceptible cells will degrade d2EGFP and will not 
produce more of the protein. Thus, toxin activity is inversely proportional to the EGFP 
fluorescence output. Productive intoxication accordingly results in the loss of d2EGFP 
fluorescence. As shown in Figure 6A, ricin reduced the Vero-d2EGFP fluorescent signal and the 
[35S]-met incorporation signal in a dose-dependent manner. The [35S]-met incorporation method, 
a common technique to monitor the activity of toxins that inhibit protein synthesis, was used as a 
basis of comparison to the Vero-d2EGFP system. These results documented that the two methods 
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were equally capable of detecting the ricin-induced inhibition of protein synthesis. Moreover, we 
also monitored toxin activity by an MTS cell viability assay. The loss of EGFP fluorescence was 
much more dramatic than the loss of cell viability after an 18-hour intoxication: a ricin ED50 of 
0.03 ng/mL was recorded by the Vero-d2EGFP assay, whereas the MTS cell viability assay 
reported an ED50 of 0.7 ng/mL (Fig. 6B). Both fluorescence and viability were measured in the 
same cell population. The loss of viability eventually mirrored the loss of fluorescence after 42 
hours of toxin exposure, with both EGFP and MTS assays documenting an ED50 of 0.02–0.04 
ng/mL (Fig. 6C). These collective results highlight several advantages of the Vero-d2EGFP 
system, including (i) relatively rapid detection of toxin activity, (ii) high sensitivity, (iii) minimal 
sample handling for data acquisition, and (iv) a noninvasive/nonterminal measurement that allows 





Figure 5. Detection of fluorescence from the Vero-d2EGFP cells.  
The fluorescence output from Vero cells (A) and Vero-d2EGFP cells (B) by confocal microscopy using a 20× objective lens. All cells in panels A and B were 
stained with DAPI and analyzed under the same exposure time. The scale bar (top left corner of panels A and B) represents 15 µm. (C) The fluorescence output 





Figure 6. Effect of ricin on protein synthesis and cell viability.  
(A) EGFP signal (filled circles) and [35S]-met incorporation signal (filled squares) of Vero-d2EGFP cells exposed to various concentrations of ricin for 18 hours. 
(B-C) Fluorescence (filled circles) and cell viability via MTS assay (open squares) were measured in the same population of Vero-d2EGFP cells after an 18-hour 
(B) or 42-hour (C) incubation with serial dilutions of ricin. Results were expressed as percentages of the maximal signal obtained from unintoxicated Vero-d2EGFP 




Time frame for loss of Vero-d2EGFP fluorescence  
To examine how quickly the Vero-d2EGFP assay can detect toxin activity, we monitored the time-
dependent decay of EGFP fluorescence from intoxicated cells (Fig. 7, circles). Using a single 
concentration of ricin (1 ng/mL), we found the EGFP signal begins to decrease after about 4 hours 
of toxin exposure and continues to decrease until 14 hours when a minimal signal of 5–8% is 
achieved. With a 2-hour half-life for d2EGFP, a signal strength corresponding to 6% of the 
unintoxicated control value could theoretically be reached 8 hours after exposure to a toxin that 
inhibits protein synthesis. The longer time frame required to reach this point for ricin-treated cells 
reflects the temporal delay between toxin binding to the cell surface and A chain delivery to its 
site of action in the cytosol (20), as well as the asynchronous nature of intoxication in a population 
of cells. These cellular events also explain why the loss of EGFP fluorescence is slower in toxin-
treated cells than in cells treated with cycloheximide, a membrane-permeant protein synthesis 
inhibitor (Fig. 7, squares). Nevertheless, our experiment demonstrated the cellular activity of ricin 
can be detected about 4 hours after toxin exposure and reaches its maximal effect on protein 





Figure 7. Time frame for loss of Vero-d2EGFP fluorescence.  
Measurements of fluorescence intensity were taken at 2-hour intervals after incubation of Vero-d2EGFP cells with 1 
ng/mL of ricin (circles) or 20 μg/mL of the protein synthesis inhibitor cycloheximide (squares). Results were expressed 
as percentages of the maximal EGFP signal obtained from untreated Vero-d2EGFP cells. The averages ± standard 




Use of the Vero-d2EGFP assay to screen for toxin inhibitors 
Disruptions to the intoxication process will permit the continued synthesis of d2EGFP in toxin-
treated cells. This principle was used to identify grape seed extract as a potent inhibitor of both 
Stx1a and Stx2a (103). The antitoxin property of grape seed extract was then confirmed with an 
independent toxicity assay that monitored the overall level of protein synthesis in cells exposed to 
Stx2 (103). In the presence of grape seed extract, the Vero-d2EGFP cells were also protected from 
ricin, Dtx, and EtxA (104). Use of the Vero-d2EGFP assay to screen for toxin inhibitors is shown 
in Figure 8. A previous screen of 26 purified polyphenolic compounds from grape extract failed 
to identify any individual inhibitor of Stx1a/Stx2a (104), so we next screened fractions from the 
grape seed extract itself for antitoxin effects. Seven polyphenolic fractions, generated by using a 
modified normal-phase high-performance liquid chromatography (HPLC) method (152) (Fig. 8A), 
were mixed with a cell-free culture supernatant containing Stx1a/Stx2a and applied to Vero-
d2EGFP cells for 18 hours. The fluorescent signal from cells exposed to toxin alone was reduced 
to 25% of the signal from unintoxicated Vero-d2EGFP cells (Fig. 8B). A similar loss of 
fluorescence was recorded for Vero-d2EGFP cells challenged with toxin in the presence of 
fractions 1–6. However, intoxicated cells co-incubated with fraction 7 retained a stronger 
fluorescent signal, representing 42% of the unintoxicated control value and a statistically 
significant difference from the intoxicated control cells (p = 0.0217, Student’s t-test). A similar 
screen indicated fractions 5–7 contain compounds that block ricin activity (Fig. 8C). In this screen, 
known polyphenol inhibitor of ricin ˗ epigallocatechin gallate (EgCg) (104, 153) ˗ was used as a 
positive control. Further separation of the compounds in fractions 5–7, combined with additional 
Vero-d2EGFP assays, could potentially identify the specific polyphenols that confer resistance to 
Stxs and/or ricin. In summary, these results show that this new system is capable of detecting the 
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activity of toxins that inhibit protein synthesis, as well as screening for toxin inhibitors. The data 
in the next section highlight the use of this GFP reporter system with flow cytometry to determine 
intoxication models, test the validity of the “one molecule” model, and investigate potential 





Figure 8. Use of the Vero-d2EGFP assay to screen for toxin inhibitors. 
(A) A modified method using normal-phase HPLC separated grape seed extract into seven fractions enriched in polyphenol monomers (catechin and epicatechin), 
dimers, trimers, or tetramers as indicated. The HPLC fractions were kindly provided by Dr. Salem Elkahoui. (B) Vero-d2EGFP cells were incubated with grape 
seed extract fractions (5% final volume) and a 1:250 dilution of a cell-free culture supernatant from an E. coli strain that expresses both Stx1a and Stx2a. After an 
18-hour incubation, EGFP fluorescence was measured with a plate reader. Results were expressed as percentages of the maximal EGFP signal obtained from a 
parallel set of unintoxicated Vero-d2EGFP cells. The means ± standard errors of the means of at least four independent experiments with six replicate samples per 
condition are shown. (C) Vero-d2EGFP cells were incubated with 0.5 ng/mL of ricin and either grape seed extract fractions (5% final volume) or 10 μg/mL of 
epigallocatechin gallate (EgCg). After an 18-hour incubation, EGFP fluorescence was measured with a plate reader. Results were expressed as percentages of the 
maximal EGFP signal obtained from a parallel set of unintoxicated Vero-d2EGFP cells. The averages ± ranges of two to four independent experiments with six 
replicate samples per condition are shown. For panels B and C, fraction 1 (F1) represents material eluted from 0 to 5 minutes; F2 represents material eluted from 




Aim II: Determine the intoxication model for a subset of AB toxins and the potential for 
cellular recovery from intoxication 
Cherubin P, Quiñones B, Teter K. 2018. Cellular Recovery from Exposure to Sub-optimal 
Concentrations of AB Toxins that Inhibit Protein Synthesis. Sci Rep. 8:2494. 
 
The results in Figure 5 show that the Vero-d2EGFP cells exhibited a fluorescence output that was 
distinguishable from the Vero cells as detected by both confocal microscopy and flow cytometry. 
Moreover, the flow cytometry results in Figure 5C indicated that the intensity of the fluorescent 
signal from the Vero-d2EGFP cells resulted in a peak that was relatively stronger than the one 
from the Vero cells. Thus, the ability to detect the Vero-d2EGFP fluorescence output and intensity 
by flow cytometry indicated that this system could be used to monitor the activity of toxin in 
individual cells. We predicted that the probability model of intoxication would yield results in 
which distinct levels of fluorescence intensity would be detected: cells with no cytosolic toxin 
would exhibit a fluorescence output similar to the unintoxicated control (i.e., no loss in protein 
synthesis as detected by the EGFP intensity), whereas cells that received at least one molecule of 
toxin would exhibit a peak with lower fluorescence output that matched the parental Vero cells. 
On the other hand, we predicted that the proportionality model would yield results showing a 
uniform loss in the EGFP intensity. In this intoxication model, individual cells within a population 
would receive varying amounts of toxin and the overall loss of EGFP intensity would be reflected 
as a uniform shift of the fluorescence peak. 
Detection of EGFP expression in Vero-d2EGFP cells by flow cytometry 
Distinct populations of Vero and Vero-d2EGFP cells were resolved by cytofluorometry when the 
two cell types were mixed together (Fig. 9). The individual peaks of background autofluorescence 
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(Fig. 9A) and EGFP fluorescence (Fig. 9B) from pure populations of Vero and Vero-d2EGFP 
cells, respectively, were both seen in mixed populations containing 1:1 (Fig. 9C) and 4:1 (Fig. 9D) 
ratios of Vero:Vero-d2EGFP cells. Although the number of cells contributing to the EGFP signal 
was reduced in the mixed populations, the peak fluorescent intensity from Vero-d2EGFP cells did 
not change. These results demonstrated it was possible to differentiate between populations of cells 
with or without EGFP expression. 
 
Consistent with previous reports (109, 154) (Fig. 7), a time-dependent reduction in the fluorescent 
intensity from cycloheximide-treated Vero-d2EGFP cells was detected by cytofluorometry and 
with a plate reader (Fig. 10). The fluorescent peak from untreated Vero-d2EGFP cells shifted to 
uniform peaks at progressively lower intensities after both a 4-hour and 8-hour incubations with 
cycloheximide, a protein synthesis inhibitor (Fig. 10A). Quantification of the remaining signals 
with both a plate reader and cytofluorometer recorded a 50% loss of fluorescence after 4 hours of 
cycloheximide treatment and an ~80% loss of fluorescence after 8 hours of cycloheximide 
treatment (Fig. 10B). Thus, our cytofluorometry system gives the same average quantitative data 
as the standard plate reader method. Using an MTS assay, only a minor loss of cell viability (22%) 
was detected after an 8-hour exposure to cycloheximide (n=2, range=3%) (data not shown). These 
pilot studies demonstrated it was possible to detect and quantify the population-wide loss of EGFP 





Figure 9. Detection of separate cell populations with or without EGFP expression.  
(A) Vero cells, (B) Vero-d2EGFP cells, (C) a 1:1 ratio of Vero:Vero-d2EGFP cells, and (D) a 4:1 ratio of Vero:Vero-
d2EGFP cells were subjected to cytofluorometry. The range of background fluorescence generated by parental Vero 
cells and a minor population of the Vero-d2EGFP cells is in black. The distribution of higher levels of fluorescence 
for the Vero-d2EGFP cells is in dark green, while light green highlights the lower level of fluorescence from a 
subpopulation of Vero-d2EGFP cells. The peak fluorescent intensity from the population of Vero-d2EGFP cells with 





Figure 10. Detection of population-wide loss of fluorescence from cycloheximide-treated Vero-d2EGFP cells. 
(A) Untreated parental Vero cells (black), untreated Vero-d2EGFP cells (green), or Vero-d2EGFP cells treated with cycloheximide for 4 hours (blue) or 8 hours 
(red) were subjected to cytofluorometry. (B) Using data collected from the same cells by either cytofluorometry (grey bars) or with a plate reader (black bars), 




Effect of short-term toxin exposure on EGFP fluorescence  
We next used cytofluorometry to examine how EGFP fluorescence was affected in Vero-d2EGFP 
cells challenged with the AB toxins ricin (Fig. 11A), Stx1a (Fig. 11B), EtxA (Fig. 11C), or Dtx 
(Fig. 11D). In each case, cells were incubated with a toxin concentration that produced a roughly 
50% reduction in EGFP fluorescence after 20 hours of incubation. Because the fluorescence 
intensity is displayed on a log rather than linear scale, the cytofluorometry profiles corresponding 
to a 50% inhibition of protein synthesis were not observed exactly midway between the 
unintoxicated Vero-d2EGFP cells with maximal EGFP expression and the parental Vero cells 
without EGFP expression. If a single molecule of toxin could elicit a cytotoxic effect, then a 50% 
loss of EGFP fluorescence would represent a bimodal cell population: half the cells would be 
intoxicated with no protein synthesis, while the other half would be unintoxicated and therefore 
producing normal levels of protein with full EGFP fluorescence. However, our cytofluorometry 
data from intoxicated cells did not detect two distinct fluorescent peaks representing background 
fluorescence and a full EGFP signal. We instead recorded a uniform, population-wide downshift 
in mean fluorescent intensity of intoxicated Vero-d2EGFP cells. A bimodal distribution of cells 
with either full EGFP expression or no EGFP expression was clearly absent from the intoxicated 
cells. These results were similar to the effects observed in Vero-d2EGFP cells that had been treated 
with cycloheximide for 4 hours and showed a population-wide downshift in their EGFP signal to 
50% of the maximal value (Fig. 10). We accordingly concluded that the entire population of Vero-
d2EGFP cells had been intoxicated, but the quantity of cell-associated toxin was only sufficient to 




A dose-dependent, population-wide loss of fluorescence was recorded for cells exposed to a range 
of concentrations for each of the tested AB toxins (Fig. 11). This effect was confirmed by 
quantifying the fluorescent signal from intoxicated cells with a plate reader before collecting the 
cells for cytofluorometry. Furthermore, the loss of protein synthesis detected by cytofluorometry 
mirrored the loss of protein synthesis detected with a plate reader. Only cells treated with Stx1a or 
EtxA showed an obvious phenotypic effect from a 20-hour challenge with higher toxin 
concentrations (Fig. 12). MTS cell proliferation assays recorded a 25% loss of viability in cells 
treated with the highest concentration of Stx1a and less toxicity in cells challenged with lower 
Stx1a concentrations or any concentration of the other three toxins (Fig. 12). For comparative 
purposes, the oxidative stress resulting from a 20-hour exposure to 1 mM H2O2 lowered cell 
viability to 56 ± 3% (n = 3, ± std. dev.) of the untreated control value (data not shown). These 
results indicated substantial cell death did not occur after a 20-hour toxin challenge despite the 





Figure 11. Dose-dependent, population-wide loss of fluorescence from toxin-treated Vero-d2EGFP cells.  
Cells were incubated for 20 hours with various concentrations of (A) ricin, (B) Stx1a, (C) EtxA, or (D) Dtx. Left 
column: using data collected from the same cells by either cytofluorometry (grey bars) or with a plate reader (black 
bars), signals from the toxin-treated cells were expressed as percentages of the value recorded for untreated Vero-
d2EGFP cells. Right column: cytofluorometry data from the same pool of intoxicated cells analyzed in the left column 
are shown, along with results from unintoxicated parental Vero cells (black lines) and unintoxicated Vero-d2EGFP 
cells (green lines). Yellow, blue, and red lines were generated from Vero-d2EGFP cells incubated with the color-




Figure 12. Cell viability after 20-hour intoxications.  
As indicated, Vero-d2EGFP cells were incubated for 20 hours with various concentrations of ricin, Stx1a, EtxA, or 
Dtx. Representative images were taken at 200× magnification. Viability, as assessed by MTS assay (n = 3, avg. ± std. 




Effect of long-term toxin exposure on EGFP fluorescence  
Our results demonstrated a single molecule of cytosolic toxin is not sufficient to completely inhibit 
protein synthesis and kill the target cell after a 20-hour incubation. However, there is a lag between 
the loss of protein synthesis and cell death. We therefore extended our incubation with ricin (Fig. 
13A), Stx1a (Fig. 13B), EtxA (Fig. 13C), or Dtx (Fig. 13D) to 36 hours in order to examine whether 
extensive cell death follows the loss of protein synthesis. Some of the intoxicated cells had 
detached from the plate by 36 hours, but cell viability (as assessed by MTS assay) was relatively 
high – between 60–80% of the unintoxicated control values (Fig. 13, left column). 
Cytofluorometry analysis of the remaining adherent cells documented a population-wide loss of 
protein synthesis (Fig. 13, center column). The fluorescent signals from these cells were 
substantially lower than the unintoxicated control values, yet most cells were still viable as 
demonstrated by a lack of staining with the apoptosis markers annexin V and 7-AAD (Fig. 13, 
right column). Viability as determined by MTS was lower than assessments made by annexin V / 
7-AAD because the MTS assay accounted for the entire cell population whereas annexin V / 7-
AAD staining only considered the subpopulation of adherent cells. Additional observations were 
recorded for a range of toxin concentrations, with the expected dose-dependent effects on cell 
morphology, viability, and protein synthesis (Fig. 14). Surprisingly, however, almost none of the 
remaining adherent cells – even those with extremely low levels of protein synthesis – were 
apoptotic. A 36-hour toxin challenge thus left a subpopulation of cells with a quantity of cytosolic 
toxin that inhibited protein synthesis but was not lethal. These observations strongly indicated that 






Figure 13. Cell survival with a long-term, toxin-induced inhibition of protein synthesis.  
Vero-d2EGFP cells were incubated for 36 hours with (A) 0.05 ng/mL of ricin, (B) 0.01 ng/mL of Stx1a, (C) 1.0 ng/mL 
of EtxA, or (D) 0.05 ng/mL of Dtx. Left column: representative images were taken at 200× magnification. Cell 
viability, as assessed by MTS assay (n = 3, avg. ± std. dev.), is indicated. Center column: red and blue lines 
(corresponding to the color-coded toxin concentrations in Figure 11) were generated from cytofluorometry analysis 
of the adherent subpopulation of toxin-treated Vero-d2EGFP cells. Unintoxicated parental Vero cells (black lines) and 
unintoxicated Vero-d2EGFP cells (green lines) were also processed for each condition. Right column: cell viability 
was recorded by cytofluorometry analysis of annexin V and 7-AAD staining (blue), while EGFP fluorescence was 
recorded by cytofluorometry (grey) or with a plate reader (black). Results are presented as percentages of the values 
obtained from unintoxicated cells. All measurements in the matched center and right columns were performed on the 




Figure 14. Effect of long-term toxin exposure on cell viability and protein synthesis (range of toxin concentrations).  
Vero-d2EGFP cells were incubated for 36 hours with various concentrations of (A) ricin, (B) Stx1a, (C) EtxA, or (D) 
Dtx. Left columns: representative images were taken at 200× magnification. Cell viability, as assessed by MTS assay 
(n = 3, avg. ± std. dev.), is indicated along with the applied dose of toxin. Center column: the subpopulation of adherent 
cells were subjected to cytofluorometry, along with unintoxicated parental Vero cells (black lines) and unintoxicated 
Vero-d2EGFP cells (green lines). Yellow, blue, and red lines were derived from Vero-d2EGFP cells incubated with 
the color-coded toxin concentration. Right column: cell viability was recorded by cytofluorometry analysis of annexin 
V and 7-AAD staining (blue), while EGFP fluorescence was recorded by cytofluorometry (grey) or with a plate reader 
(black). Results are presented as percentages of the values obtained from unintoxicated cells. All measurements in the 
matched center and right columns were performed on the same population of cells. These experiments were performed 
at the same time as the data presented in Figure 13 and, for comparative purposes, include the toxin concentrations 




Cellular recovery from exposure to AB toxins 
Our collective data suggested cells can tolerate low levels of cytosolic toxin and the partial 
inhibition of protein synthesis without a terminal effect. Thus, cells could potentially recover from 
intoxication. To further examine this possibility, we challenged Vero-d2EGFP cells with ricin (Fig. 
15A), Stx1a (Fig. 15B), EtxA (Fig. 15C), or Dtx (Fig. 15D) for 20 hours. Toxins were applied at 
concentrations that were at or below the 20-hour ED50 values. One set of cells for each applied 
toxin was processed for cytofluorometry, while another set was washed and incubated in toxin-
free medium for an additional 48-hour before cytofluorometry. The population-wide loss of EGFP 
fluorescence recorded after 20 hours of intoxication demonstrated all cells had a cytosolic pool of 
toxin at this time, as indicated by the observed downshift in peak fluorescence intensity (Fig. 15, 
left column). Cells that were chased in toxin-free medium for 48 hours exhibited higher levels of 
fluorescence than were recorded after the initial 20-hour toxin challenge (Fig. 15, center column), 
and a substantial pool of viable, adherent cells remained at the end of the chase (Fig. 15, right 
column). For these experiments, the quantity of cytosolic toxin present at 20-hour of intoxication 
was therefore insufficient to completely inhibit protein synthesis and kill the entire population of 
intoxicated cells. Removal of the toxin after a 20-hour exposure consequently allowed most cells 
to recover from the toxin-induced inhibition of protein synthesis. 
 
As expected, recovery from intoxication was dependent on the applied dose of toxin: cells exposed 
to higher toxin concentrations did not return to high levels of EGFP fluorescence by the end of the 
68-hour experiment, and substantial cell death was recorded (Fig. 16). These experiments were 
performed at the same time as the experiments presented in Figure 15 and are shown as a separate 
figure to emphasize cells can recover from sub-optimal levels of toxin (Fig. 15) but not all toxin 
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concentrations (Fig. 16). Combined, Figures 15 and 16 present data with the three toxin 
concentrations used throughout this work. Bimodal fluorescent signals were detected for cells that 
were exposed to intermediate concentrations of Stx1a or EtxA, which demonstrated our system 
could detect an all-or-nothing signal distribution with intoxicated cells. It also indicated protein 
synthesis had been completely inhibited in one subpopulation of toxin-challenged cells, while 
another subpopulation had completely recovered from intoxication and produced normal levels of 
protein. The bimodal fluorescent profiles detected in many conditions from the 68-hour experiment 
would skew the mean fluorescent intensities, so the EGFP signals were not quantified. However, 
the population-wide loss of protein synthesis recorded at 20-hour of intoxication for all toxin 
concentrations confirmed every cell had at least one molecule of cytosolic toxin at this time. As 
such, the greater level of cell death resulting from exposure to higher toxin concentrations could 
not be attributed to a greater number of intoxicated cells (i.e., the probability model of 
intoxication). Instead, transient exposure to higher toxin concentrations apparently produced a 
greater quantity of cytosolic toxin that overwhelmed the cellular capacity to withstand intoxication 
(i.e., the proportionality model of intoxication). Productive intoxication thus requires either 
transient exposure to high toxin concentrations or continual exposure to sub-optimal toxin 
concentrations. The exact quantity of toxin required for cell death by either of these mechanisms 





Figure 15. Cellular recovery from intoxication.  
Vero-d2EGFP cells were incubated with (A) 0.025 ng/mL of ricin, (B) 0.001 ng/mL of Stx1a, (C) 1.0 ng/mL of EtxA, 
or (D) 0.01 ng/mL of Dtx for 20 hours and then chased for 48 hours in the absence of toxin. Blue and yellow lines 
(corresponding to the color-coded toxin concentrations in Figures 11 and 14) were generated from cytofluorometry 
analysis of toxin-treated Vero-d2EGFP cells at the end of the 20-hour toxin incubation (left column) or 48-hour chase 
(center column). Unintoxicated parental Vero cells (black lines) and unintoxicated Vero-d2EGFP cells (green lines) 
were also processed for each condition. Percentages represent the strength of the EGFP signal from intoxicated cells 
in comparison to unintoxicated cells. Right column: representative images of cells at the end of the 48-hour chase 
were taken at 200× magnification. Cell viability, as assessed by MTS assay (n = 3, avg. ± std. dev.) or annexin V/7-





Figure 16. Dose-dependent recovery from intoxication (additional toxin concentrations).  
Vero-d2EGFP cells were incubated with various concentrations of (A) ricin, (B) Stx1a, (C) EtxA, or (D) Dtx for 20 
hours and then chased for 48 hours in the absence of toxin. Left columns: yellow, blue, and red lines were derived 
from cytofluorometry analysis of toxin-treated Vero-d2EGFP cells at the end of the 20-hour toxin incubation or the 
end of the 48-hour chase. Unintoxicated parental Vero cells (black lines) and unintoxicated Vero-d2EGFP cells (green 
lines) were also processed for each condition. Right columns: at the end of the 48-hour chase, representative images 
of cells initially exposed to the stated toxin concentrations were taken at 200× magnification. Cell viability, as assessed 
by MTS assay (n = 3, avg. ± std. dev.) or annexin V/7-AAD staining of the same cell population processed for EGFP 




Aim III: Investigate factors that contribute to the cellular potency of Stx subtypes 
Cherubin P, Fidler D, Quiñones B, Teter K. Bimodal Response to Shiga Toxin 2 Subtypes Results 
from Relatively Weak Binding to the Target Cell. Infection and Immunity. Under revision. 
 
Stx1a is more potent to Vero cells than Stx2 subtypes. The factors contributing to the difference 
in cellular potency are mostly unknown. Therefore, we used our cytofluorometry-based system to 
examine the differential potency between Stx subtypes. Since we already monitored the activity of 
Stx1a in Aim II using our new system, the goal of Aim III was to monitor the activity of Stx2 
subtypes in individual cells and compare the results with that obtained for Stx1a. A comparison 
between the results obtained for these Stx subtypes will provide better insights into their 
differential cytotoxicity.  
Stx1a is more potent against cultured cells than Stx2 subtypes 
Vero-d2EGFP cells were used to establish the relative potencies of Stx1a, Stx2a, and Stx2c. Cells 
were seeded on a 96 well plate overnight before an 18-hour incubation with 10-fold serial dilutions 
of each toxin. Stx1a was very effective at inhibiting protein synthesis in the target cells, with an 
ED50 of 0.005 ng/mL (Fig. 17A, triangles). Stx2a, on the other hand, was less effective than Stx1a, 
with a 140-fold higher ED50 of 0.7 ng/mL (Fig. 17A, circles). An ED50 of 10 ng/mL was recorded 
for Stx2c (Fig. 17A, squares), which was 2,000-fold less toxic than Stx1a. Our results were 
consistent with previous reports on the relative cellular activities of Stx1a, Stx2a, and Stx2c (120, 
130, 131). As previously observed when examining the toxicity of Stx1a in Vero cells (Figures 11, 
12), there was a greater level of protein synthesis inhibition than cell death after an 18-hour 
intoxication with Stx2a and Stx2c subtypes (Fig. 17A-B). Extending the toxin challenge to 36 
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hours resulted in greater cell death than seen at 18 hours (Fig. 17C). ED50 values for cell viability 
after a 36-hour toxin exposure demonstrated Stx1a (ED50 of 0.06 ng/mL) was 17-fold more potent 
than Stx2a (ED50 of 1 ng/mL) and 667-fold more potent than Stx2c (ED50 of 40 ng/mL). Thus, 
consistent with previous reports (130, 131, 155), Vero cells were much more sensitive to Stx1a 
than either Stx2a or Stx2c as determined by both protein synthesis and cell viability assays. 





Figure 17. Relative potencies of Stx subtypes.  
Vero-d2EGFP cells were challenged with 10-fold serial dilutions of Stx1a (triangles), Stx2a (circles), or Stx2c 
(squares). The extent of protein synthesis after 18 hours of incubation (A) or cell viability after 18 hours (B), 36 hours 
(C), and 72 hours (D) of incubation was then recorded. Values for toxin-treated cells were expressed as percentages 
of the maximal signal obtained from unintoxicated control cells. Data represent the means ± standard errors of the 




Bimodal cellular response to Stx2 subtypes 
With our Vero-d2EGFP system, the toxin-induced loss of protein synthesis can be detected with a 
plate reader or by flow cytometry. Both methods recorded the same level of toxin activity on cells 
incubated overnight with Stx1a (Fig. 11). Previous analyses using flow cytometry further 
documented the population-wide loss of protein synthesis in cells exposed to Stx1a (Fig. 11), 
which was replicated here: increasing concentrations of Stx1a elicited an increasingly dramatic 
downshift in the peak fluorescent intensity of Vero-d2EGFP cells (Fig. 18A). This effect was not 
seen for cells challenged with Stx2a (Fig. 18B) or Stx2c (Fig. 18C). Both toxins generated a 
bimodal fluorescent profile from the intoxicated Vero-d2EGFP cells in which one subpopulation 
of cells maintained the peak fluorescent intensity observed for unintoxicated cells and the other 
subpopulation exhibited reduced levels of fluorescent intensity (i.e., protein synthesis). A 
substantial number of Vero-d2EGFP cells were therefore resistant to moderate doses of Stx2a and 
Stx2c, with no appreciable loss of protein synthesis. The subpopulation of Vero-d2EGFP cells that 
maintained the peak fluorescent intensity after challenge with Stx2a or Stx2c were not intrinsically 
resistant to the toxins, however: the subpopulation of resistant cells progressively decreased with 
increasing toxin concentrations (Fig. 18B-C). This indicated Stx2a and Stx2c can generate 
substantial, population-wide decreases in protein synthesis when present at relatively high toxin 





Figure 18. Distinct cellular responses to Stx subtypes.  
Vero-d2EGFP cells were subjected to cytofluorometry after an 18-hour incubation with the stated concentrations of Stx1a (A), Stx2a (B), or Stx2c (C). 
Unintoxicated parental Vero cells (black lines) and unintoxicated Vero-d2EGFP cells (green lines) were also processed for each condition. One of three 




Uniform distribution of Gb3 and Gb4 in the population of Vero cells 
Globoside Gb3 serves as a functional surface receptor for all Stx subtypes including Stx2e, which 
preferably binds to the Gb4 surface receptor (156-159). Gb4 also has a moderate affinity for Stx1a 
and a weak affinity for Stx2a or Stx2c (137, 138). We accordingly predicted that the Stx2a/Stx2c-
resistant subpopulation of Vero-d2EGFP cells lacked Gb3 but still expressed the alternate Gb4 
receptor with preferential affinity for Stx1a. To test this hypothesis, we examined the distribution 
of Gb3 and Gb4 in a population of Vero cells. Analysis by flow cytometry documented a uniform 
distribution of Gb3 (Fig. 19A) and Gb4 (Fig. 19B) in cell populations exposed to Gb3 or Gb4 
primary antibodies and fluorophore-labeled secondary antibodies, which, in agreement with 
previous studies (159-161), confirmed that the Vero cells employed for these experiments 
contained both Gb3 and Gb4 cell surface receptors. 
 
Vero cells were next incubated with both Gb3 and Gb4 antibodies and then the corresponding 
fluorophore-labeled secondary antibodies. Preliminary experiments confirmed the signals from 
each fluorophore did not bleed into the emission wavelength of the other fluorophore (data not 
shown). A scatter plot of the resulting data revealed a linear relationship between the two 
globosides, indicating Gb3 content was proportional to Gb4 content (Fig. 19C). Only 3% of cells 
were positive for Gb3 but not Gb4 (lower right quadrant), and only 5% of cells were positive for 
Gb4 but not Gb3 (upper left quadrant). Therefore, contrary to our hypothesis, the collective 
experiments with Gb3 and Gb4 staining suggested that nearly the entire population of Vero cells 
express both Gb3 and Gb4. The minor population of Gb3
-/Gb4
+ cells (5%) could not account for the 
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relatively high number of cells that were completely resistant to moderate concentrations of Stx2a 





Figure 19. Gb3 and Gb4 distribution in Vero cells.  
Gb3 and Gb4 antibodies were applied independently (A-B) or simultaneously (C) to Vero cells before analysis by cytofluorometry. (A) Staining pattern for the 
combination of a rat antibody against Gb3 and an APC-conjugated goat anti-rat IgG antibody (red line). (B) Staining pattern for the combination of a rabbit antibody 
against Gb4 and a PE-conjugated donkey anti-rabbit IgG antibody (red line). Cells incubated with the secondary antibody alone (black lines in panels A and B) 
were processed as well. (C) The combined staining patterns for Gb3 and Gb4 are represented on a scatter plot of 10,000 individual cells. Cells exposed to the 




The B subunit of Stx1a binds to host cells with better efficiency than that of Stx2a 
To further examine the dose-dependent binding of the B subunits of Stx1a or Stx2a with their 
surface receptors, Vero cells were incubated with the fluorophore-labeled B subunits for 30 
minutes at 4°C before analysis by flow cytometry (Fig. 20). A uniform distribution of toxin binding 
was observed in cells exposed to the B subunits of either Stx1a (Fig. 20A) or Stx2a (Fig. 20B). As 
seen for the distribution of Gb3 and Gb4 (Fig. 19), there was no obvious subpopulation of cells that 
did not bind the monomeric B subunit. The labeling efficiency for the B subunit of Stx1a (0.093) 
was slightly weaker than the labeling efficiency for the B subunit of Stx2a (0.13), yet a stronger 
cell-binding signal was recorded for the B subunit of Stx1a than Stx2a when an equivalent amount 
of B subunit (2 µg) was tested (Fig. 20C). Figure 20D further shows that 0.5 μg of the Stx2a B 
subunit was required to generate the same cell-binding signal as 0.2 μg of the Stx1a B subunit, 
indicating a 2.5-fold more binding for the B subunit of Stx1a. A similar observation was seen for 
other pairs of toxin concentrations (data not shown). We also noted that binding of the Stx2a B 
subunit appeared to reach saturation at 1 µg/mL, whereas 2 µg/mL of the Stx1a B subunit produced 
a stronger cell-associated signal than its 1 µg/mL concentration. This observation might reflect the 
relatively higher affinity of Stx1a for both Gb3 and Gb4 in comparison to Stx2a: binding of the 
Stx2a B subunit may reach saturation when all Gb3 receptors are occupied, but the B subunit of 
Stx1a could bind additional Gb4 receptors in addition to the saturated Gb3 receptors. Our collective 
observations were consistent with reports that have documented a higher affinity for the interaction 




Competition assays further emphasized the different affinities of Stx1a and Stx2a for Vero cells. 
In this experiment, a fixed concentration of Stx1a (0.1 ng/mL) was mixed with one of two different 
concentrations of Stx2a (1 ng/mL and 10 ng/mL). Flow cytometry was then used to assess the 
effect on protein synthesis after 18 hours in the presence of Stx1a, Stx2a, or both. Cells exposed 
to Stx1a alone (red peak) exhibited a uniform drop in protein synthesis, whereas cells exposed to 
either concentration of Stx2a alone (orange and blue peaks) exhibited a bimodal response (Fig. 
21A). These results were consistent with the data presented in Figure 18. Cells exposed to toxin 
mixtures consisting of a 10-fold (orange) or 100-fold (blue) excess of Stx2a when compared to 
Stx1a exhibited a uniform drop of protein synthesis that was similar to the fluorescent profile of 
cells exposed to Stx1a alone (Fig. 21B). Thus, Stx2a does not appear to effectively compete with 
Stx1a for binding to the target cell. Previous studies have documented the reduced potency of 
Stx2a in cell culture and animal models when mixed with the Stx1a B subunit (162), but our current 
work ˗ which was only possible because of the different population responses to Stx1a vs. Stx2a ˗ 
provides the first experimental evidence that Stx1a holotoxin can out-compete Stx2a holotoxin in 





Figure 20. Dose-dependent association of Stx1a and Stx2a with the cell surface.  
Vero cells were processed for cytofluorometry after a 30 minutes 4°C incubation with the fluorophore-labeled B subunits of Stx1a or Stx2a. The intensity of the 
Alexa Fluor® 594 dye indicates the extent of Stx binding. (A-B) Cells were incubated without toxin (black line) or in the presence of various quantities of either 
the Stx1a B subunit (A) or Stx2a B subunit (B): 0.2 μg (magenta line), 0.5 μg (yellow line), 1.0 μg (blue line), or 2.0 μg (red line), all in 500 µL volume. (C) The 
signals recorded for 2 μg of either the Stx1a B subunit (red line) or Stx2a subunit (blue line) were overlaid on the same plot. (D) The signals recorded for 0.2 μg of 
the Stx1a B subunit (red line) and 0.5 μg of the Stx2a B subunit (blue line) were overlaid on the same plot. One of three representative experiments is shown for 





Figure 21. Competition between Stx1a and Stx2a.  
Vero-d2EGFP cells were processed for cytofluorometry after an 18-hour incubation with Stx1a and Stx2a alone (A), or as a mixture (B). The red peak in A denotes 
incubation of cells with 0.1 ng/mL of Stx1a, whereas the blue and orange peaks denote incubation of cells with 1 ng/mL and 10 ng/mL of Stx2a, respectively. In 
panel B, the orange peak represents incubation of cells with a mixture of 0.1 ng/ml Stx1a and 1 ng/ml Stx2a, whereas the blue peak represents incubation of cells 




The identity of the B pentamer is responsible, in part, for the bimodal response observed with Stx2 
subtypes 
Our results suggested that the different cellular responses to Stx1a vs. Stx2a resulted from more 
Stx1a binding to the target cell (Fig. 20). In this model, the origin of the toxin B subunit may 
determine whether the cellular response to intoxication is uniform or bimodal. To test this model, 
we used two hybrid toxins which consisted of either the A1 subunit from Stx2a with the A2 and B 
subunits from Stx1a (Stx 211) or the A1 subunit from Stx1a with the A2 and B subunits from 
Stx2a (Stx 122) (Fig. 4). It has been shown that replacing the binding subunit of Stx2a with that 
of Stx1a results in an increase toxicity for Stx2a, whereas replacing the binding subunit of Stx1a 
with that of Stx2a results in a decrease in toxicity for Stx1a (139). The A2 linker is matched to its 
cognate B subunit in these chimeric toxins because it is important for holotoxin stability (21, 22, 
139). Both toxins were isolated from the cell extracts of transformed E. coli BL21(DE3)pLysS. 
The control experiment in Figure 22A demonstrates the cell extract from untransformed E. coli 
did not have an effect on protein synthesis when added to the culture medium of Vero-d2EGFP 
cells. Additional control experiments ensured cell extracts containing Stx1a holotoxin (Fig. 22B) 
or Stx2a holotoxin (Fig. 22C) produced the expected cellular responses that were previously 
documented using purified toxins (i.e., a uniform loss of protein synthesis in cells exposed to Stx1a 
and a bimodal response in cells exposed to Stx2a) (Fig. 18). Vero-d2EGFP cells challenged with 
the Stx 211 hybrid toxin exhibited a uniform downward shift in protein synthesis, similar to that 
of Stx1a holotoxin (Fig. 22D). In contrast, exposure to the Stx 122 hybrid toxin produced a bimodal 
response from the Vero-d2EGFP cells that was similar to the response elicited by Stx2a holotoxin 
(Fig. 22E). These results suggest the A2 fragment and B subunit of a Stx contribute to the different 
responses between Stx1a and Stx2a as observed by flow cytometry, resulting in a uniform profile 
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for toxins containing the B subunit of Stx1a and a bimodal profile for toxins containing the B 





Figure 22. Cellular response to hybrid Stxs.  
Vero-d2EGFP cells were processed for cytofluorometry after an 18-hour incubation with 10-fold serial dilutions of cell extracts from a non-pathogenic (Stx-) BL21 
E. coli strain that was untransformed (A) or transformed with expression vectors encoding Stx1a holotoxin (B), Stx2a holotoxin (C), the 211 hybrid toxin consisting 
of the A1 subunit from Stx2a with the A2 and B subunits from Stx1a (D), or the 122 hybrid toxin consisting of the A1 subunit from Stx1a with the A2 and B 




CHAPTER 5: DISCUSSION 
AB toxins are so potent that a single molecule of cytosolic toxin is thought to be sufficient for the 
complete inhibition of protein synthesis and cell death. The supporting evidence for this model is 
based upon extrapolations from in vitro studies with toxin serial dilutions or kinetic analyses of 
intoxication (6, 86, 110). It would be nearly impossible to directly demonstrate that only one or a 
few toxin molecules are in the cytosol of a dead cell. As an alternative approach, we have shown 
cells with a toxin-induced inhibition of protein synthesis can, upon removal of sub-optimal toxin 
concentrations from the medium, survive the toxin challenge and restore normal levels of protein 
synthesis. Our results show that one molecule of Stx1a, ricin, EtxA, and Dtx is not sufficient to 
completely inhibit protein synthesis and lead to cell death. Moreover, we showed that cells can 
recover from intoxication. The key experiment involved a 20-hour toxin challenge and 48-hour 
recovery period (Fig. 15, 16). At least one molecule of toxin must have been present in the cytosol 
after 20 hours of intoxication in order to have an inhibitory effect on protein synthesis, yet the 
intoxicated cells survived, with normal levels of protein synthesis, 68 hours after the initial toxin 
challenge. We accordingly conclude that one or a few molecules of cytosolic toxin are not 
sufficient to kill the cell.  
 
Catalytic toxin A chains were originally thought to be stable in the host cytosol (2, 112, 114, 163), 
although direct evidence for this assertion is lacking. Theoretically speaking, a single molecule of 
stable cytosolic toxin could, with time, block all protein synthesis and ultimately kill the cell. 
However, there are evidence suggesting that toxin A chains are not stable in the cytosol: several 
studies have directly or indirectly documented the proteasome-dependent degradation of cytosolic 
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toxin (6, 116-118). The turnover of cytosolic toxin is apparently faster than the time required for 
a single toxin molecule to inactivate enough ribosomes for the cessation of protein synthesis and 
corresponding cell death. Hence, as demonstrated here, productive intoxication requires either 
ongoing toxin delivery to the cytosol or a large initial bolus of cytosolic toxin. 
 
The proportionality model of intoxication suggests the cytosolic stability of the toxin A chain will 
directly impact the capacity for recovery from intoxication, which is consistent with our 
observations for Dtx. As shown in Figures 15 and 16, cells could only recover from a minimal 
initial inhibition of protein synthesis by this relatively stable toxin (115). Other reports further 
suggest the extent of intoxication is linked to the efficiency of toxin clearance from the cytosol. 
For example, cellular resistance to ricin or EtxA results from enhanced degradation of the cytosolic 
toxin (117-119). Conditions that impede the turnover of cytosolic toxin likewise generate cellular 
sensitivity to ricin or Stx1a (6, 116, 117, 119). In fact, new studies have shown a protective effect 
by ricin antibodies post-toxin exposure (164, 165). These collective observations thus suggest that 
the extent of intoxication is directly linked to how much toxin is in the cytosol, with the amount 
of cytosolic toxin representing a balance between toxin delivery to the cytosol and toxin removal 
from the cytosol. 
 
Stx, ricin, and EtxA enter the host cell by receptor-mediated endocytosis and follow an inefficient 
transport to the ER before reaching their cytosolic targets. Dtx, on the other hand, enters the host 
cell and reaches its cytosolic target directly from the endosomes using a more efficient process. 
Thus, the faster delivery and stability of Dtx seem to correlate to higher amount of total cytosolic 
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toxin, which in turn explain the higher cellular potency we observed for Dtx in comparison to 
Stx1a, ricin, and EtxA (Fig. 11, 14).  
 
Our study does not minimize the extreme potency of AB toxins, but it does challenge the long-
standing assertion that a single or few molecules of cytosolic toxin are sufficient to completely 
inhibit protein synthesis and kill the cell. As previously stated, this model was formulated before 
the proteasome-mediated clearance of cytosolic toxin was characterized. Cells treated with a 
proteasome inhibitor have been shown to be sensitized to Stx and other AB toxins (6, 116, 117, 
166). Likewise, the accelerated degradation of cytosolic toxin produces a toxin-resistant phenotype 
(117, 118, 167-169). Because there is a lag between the inhibition of protein synthesis and cell 
death (Fig. 6, 17), the clearance of cytosolic toxin provides an opportunity to restore normal levels 
of protein synthesis and recover from transient exposure to sub-optimal toxin concentrations. Thus, 
conditions that prevent efficient and/or ongoing toxin delivery to the cytosol could allow a cell to 
withstand the effects of intoxication. This was demonstrated here by removing low levels of toxin 
from the medium. Such observations provide experimental support for the development of 
inhibitors and post-exposure therapeutics that restrict, but do not necessarily completely block, 
toxin delivery to the host cytosol. Experimental support for this model has been previously 
generated in cell culture using neutralizing antibodies against Stx2a or the plant toxin ricin (165, 
170, 171). In these studies, cellular protection was observed under conditions that neutralize 
intracellular ricin as well as conditions that interfered with ricin and Stx2a transport.  
 
Our observations also indicate the effective application of an anti-cancer immunotoxin (88, 112) 
will require either ongoing delivery or efficient initial delivery of the toxin A chain into the cytosol 
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of a targeted cancer cell. Our results suggest that a threshold of cytosolic toxin is required to cause 
cell death. Furthermore, our observations indicate that the extent of intoxication represents a 
balance between toxin delivery to the cytosol and toxin clearance from the cytosol. Cells that were 
affected by at least one molecule of Stx1a, ricin, EtxA, and Dtx survived the toxin challenge and 
recovered from intoxication. Thus, these findings suggest that in order to elicit and maintain a 
desired toxic effect to kill a cancer cell, there must be enough toxin in the cytosol to overcome its 
constant turnover as well as compensatory host mechanisms such as the synthesis of new 
ribosomes. Overall, our work indicates that the development of effective immunotoxins may 
require repeated application and/or the use of more stable toxins. 
 
Most quantitative assays that monitor the toxin-induced inhibition of protein synthesis average the 
results from a population of cells (89, 172). Using these methods, it is not possible to differentiate 
between intoxicated and unintoxicated cells within the population. As an alternative approach, we 
used flow cytometry in conjunction with a Vero-d2EGFP cell line that expresses an EGFP variant 
with a 2-hour half-life. This allowed us to record the toxin-induced inhibition of protein synthesis 
and resulting loss of EGFP fluorescence from individual cells in the population of toxin-challenged 
cells. Using our cytofluorometry-based system, we were able to differentiate the probability model 
from the proportionality model of intoxication. Our system monitored toxin activity in individual 
cells and allowed us to detect cells that were affected from those that were not. In our system, 
toxin-affected cells exhibit a lower fluorescence peak, whereas cells unaffected by toxin maintain 




Our cytofluorometry-based system also allowed us to make a contribution to the understanding of 
the cellular basis for the different potencies of Stx1a and Stx2 subtypes. The factors contributing 
to the higher toxicity of Stx1 subtypes to Vero cells are poorly understood and/or unknown. All 
Vero-d2EGFP cells exposed to Stx1a were affected by the toxin and thus, exhibited a uniform drop 
in protein synthesis that was detected by the EGFP signal intensity. Even at the lowest 
concentration of Stx1a (0.001 ng/mL), a minor population-wide drop in fluorescent intensity was 
detected (Fig. 11B, 18A). In contrast, the bimodal fluorescent profile of Vero-d2EGFP cells 
exposed to Stx2a or Stx2c indicated a subpopulation of the toxin-challenged cells were completely 
resistant to these toxins and therefore maintained their full level of protein synthesis. This bimodal 
response to Stx2a or Stx2c has not been previously reported. 
 
The uniform response to Stx1a and bimodal response to Stx2a could not be attributed to the lack 
of Gb3 receptor in a subpopulation of cells. However, the cells did bind more Stx1a than Stx2a. 
Stx1a could also out-compete Stx2a, as cells challenged with a combination of Stx1a and Stx2a 
exhibited a population-wide loss of protein synthesis even when there was a 100-fold excess of 
Stx2a over Stx1a. Additional studies with hybrid toxins indicated the uniform vs. bimodal response 
to intoxication is linked to the subtype of the B subunit, with the B subunit from Stx2a producing 
a bimodal response. Our collective results suggest the bimodal response to Stx2a or Stx2c involves 
(i) relatively weak binding between Stx2a and the host cell that reduces the total cell-associated 
pool of Stx2a in comparison to Stx1a, and (ii) the need to accumulate a substantial pool of cytosolic 
toxin to inhibit protein synthesis and induce cell death. These observations further suggest the 
inhibition of protein synthesis and resulting cell death from Stx2a or Stx2c requires a threshold 
concentration of cell-associated toxin, which is consistent with our conclusions for Aim II.  
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The number of Stx2-resistant cells decreased with increasing toxin concentration, which indicated 
there is no subpopulation of Vero-d2EGFP cells with intrinsic resistance to Stx2 subtypes. We did 
not observe a bimodal pattern for Gb3 content, so it is unlikely that the bimodal response to 
intoxication was due to a subpopulation of cells that lack Gb3. Instead, the relatively poor binding 
of Stx2a seemed to limit the amount of cell-associated toxin to the point where some cells were 
resistant to intoxication. In contrast, the relatively strong binding of Stx1a to its target cell ensured 
all cells in the population received an effective dose of cytosolic toxin.  
 
Data gathered from various epidemiological studies indicate that patients carrying E. coli O157:H7 
strains that only express Stx2a are more prone to develop HUS (125, 173-176). The factors 
contributing to the observed difference in potency are not fully understood. In an attempt to 
understand the differential potency between Stx subtypes, localization experiments have shown 
that Stx1a mostly accumulates in the lungs of mice, while Stx2a does not (177). It has been 
suggested that the lungs serve as a “sink” where Stx1a strongly binds to toxin-resistant cells, 
thereby preventing the toxin from reaching the more sensitive kidney cells. Moreover, Stx1a has 
been shown in vivo to protect mice intoxicated with Stx2a (178). The B subunit of Stx1a was also 
shown to reduce the potency of Stx2a in mice and the cytotoxicity of Stx2a to Vero cells (162). In 
our study, we further demonstrated that Stx2a could not effectively compete with Stx1a for 
intoxication of Vero-d2EGFP cells: cells exposed to a 1:100 mixture of Stx1a to Stx2a still 
produced the uniform loss of fluorescence characteristic of the Stx1a response. We believe that the 
low receptor affinity of Stx2 subtypes may be a factor that enables the toxin to escape lung cells. 
Moreover, it is possible that the higher catalytic activity of the Stx2a A subunit is a contributing 
factor to its higher potency in animal studies. The present study highlighting the role of the binding 
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subunit in the differential cellular toxicity of Stx subtypes provides additional evidence to better 
understand how Stx2a evades lung cells and how Stx1a suppresses the potency of Stx2a. Thus, 
these collective observations suggest that the binding subunit of Stx subtypes is an important factor 
that contributes to potency and disease pathogenicity. 
 
As we have previously demonstrated with Stx1a and other AB toxins (Aim II), cell death is not an 
inevitable outcome of toxin binding or even toxin activity in the cytosol. Therapeutic approaches 
that involve toxin neutralization at a post-exposure stage could thus be effective strategies for the 
treatment of STEC infections. These strategies may be particularly effective against STEC strains 
that express a Stx2 subtype, as the dose-dependent bimodal response to Stx2a or Stx2c suggests it 
is possible to reduce the cell-associated pool of toxin to the point where cells are either completely 
resistant to intoxication or more prone to recover from a partial inhibition of protein synthesis. 
Toxin inactivation could involve the administration of inactive Stx1a variants that compete with 
Stx2a for binding to target cells. This approach has been shown to reduce the toxicity of Stx2a in 
mice (162, 178). Neutralizing antibodies could likewise reduce the amount of Stx2a that reaches 
the cytosol of host cells, either by blocking adherence to the target cell or disrupting intracellular 
toxin trafficking (179, 180). 
 
Our data showing Stx1a is more potent against cultured cells than Stx2 subtypes were consistent 
with published work (130, 131, 155). Our observation that Stx2a binds to target cells with lower 
affinity than Stx1a is also consistent with the literature (130, 135, 136, 138). However, those 
previous studies averaged the results from an entire population of toxin-challenged cells and could 
not detect variable cellular responses within the population. The use of a cytofluorometry-based 
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intoxication system allowed us, for the first time, to document the bimodal population response to 
Stx2 subtypes that appears to result from the relatively low affinity of toxin binding to the cell 
surface. These findings provide a new basis to better understand the differential toxicity between 
Stx subtypes and establish a conceptual foundation for the development of post-exposure toxin 
therapeutics that function by lowering the amount of toxin that reaches the host cytosol. 
 
In conclusion, we developed a new system to study the cellular potency of AB toxins that inhibit 
protein synthesis. Using the newly developed system, we showed that a single or a few molecules 
of AB toxin are not sufficient to completely inhibit protein synthesis and ultimately kill the host 
cell. Additionally, we showed for the first time that cells can recover from intoxication. Lastly, we 
showed that cells intoxicated with Stx2 subtypes exhibit a bimodal cellular response, while cells 
intoxicated with Stx1a exhibit a uniform cellular response. Additional experiments on the different 
cellular response to Stx subtypes showed that the cellular response we observed is mainly due to 
the identity of the B-pentamer. Thus, this study provided a set of new evidence to help elucidate 
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